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Regulation of Transcription and Analysis of Drug Targets 
 in Lymphoma and Myeloma Cells 
 
Sophia C.E. Bolick 
 
ABSTRACT 
 
 Hematological malignancies, such as lymphomas and myelomas, have low cure 
rates or remain refractory to treatment, although advances have been made in treatment 
regimens for these patients.  Questions still remain as to what is occurring in these cells 
on a molecular level, specifically at the level of gene transcription.  The positive 
regulatory domain I binding factor 1 (PRDI-BF1) has been shown to directly repress 
genes required for cell proliferation and maintenance of the B cell phenotype, however 
very little is known as to its regulation.  The first study presented in this dissertation 
demonstrates regulation of the PRDM1 gene occurs primarily at the level of transcription 
in B cell receptor (BCR)-stimulated lymphoma cells and myeloma cells.  It also 
demonstrates PU.1 binding is involved in BCR-mediated activation of lymphoma cells.  
Most importantly, this study presents evidence of a promoter poised and primed for 
activation in lymphoma cells.  These studies lay the groundwork for the second study 
which examines modulation of PRDM1 expression in lymphoma cells by 
chemotherapeutic agents.  Induction of PRDI-BF1 in lymphoma cells negative for 
PRDM1 gene expression correlates with increased apoptosis, which has important 
therapeutic implications for treatment of lymphomas.  One common problem that arises 
 xiii 
in treatment of cancer patients is the eventual emergence of a drug resistant population of 
cells.  Identifying specific drug targets and whether they confer drug resistance is an 
important area of study, which is the focus of the third study presented in this 
dissertation.  It demonstrates the response of myeloma cells to treatment with the 
farnesyltransferase inhibitor (FTI)-277 and examines whether known mechanisms of 
drug resistance in these cells are responsible for cross-resistance to FTI-277.   
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Chapter One 
General Introduction 
 
B cell to plasma cell differentiation 
 All hematopoietic cells are derived from pluripotent stem cells, which can self-
renew and give rise to progenitor cells in the myeloid and lymphoid lineages.  At each 
step in the development process, these progenitors become more and more differentiated 
(160).  Early lymphoid progenitors start to express recombination activating genes 1 and 
2 (Rag1 and Rag2) and can recombine at the immunoglobulin heavy chain (IgH) locus 
(101).  They can further differentiate into either bone marrow common lymphoid 
progenitors (CLPs) or early T-cell lineage precursors.  CLPs give rise to a multitude of 
cells of the lymphoid lineage, such as B cells, T cells, dendritic cells, and natural killer 
cells.  With the onset of expression of the cell surface marker B220, CLPs are committed 
to the B cell differentiation process.  Cells then begin to express CD19 and completion of 
IgH diversity (DH)-to-joining (JH) gene segment rearrangement by pre-B cells occurs.  
Rearrangement of the IgH locus at its variable (V) region continues until VH-DJH alleles 
are generated.  Rag1 and Rag2 expression is terminated and the product of IgH locus 
rearrangement is expressed on the cell surface.  It forms the pre-B cell receptor (BCR) by 
assembling with the immunoglobulin (Ig) light chains and signaling molecules Igα and 
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Igβ, defining the immature B cell stage of development (160, 175).  Immature B cells are 
also characterized by expression of surface IgM (213).  
 Immature B cells expressiong surface IgM migrate to the spleen from the bone 
marrow for further development (213).  A small minority become naïve marginal-zone B 
cells, homing to the splenic marginal zone (201).  Most become naïve follicular B cells, 
circulating to follicles in the spleen, lymph nodes, and bone marrow.  At this point, they 
either encounter antigen or die.  Those encountering antigen will either further 
differentiate to a plasma cell or form germinal centers, at which point they become 
memory B cells or undergo differentiation to a plasma cell (figure 1, derived from (160, 
236)).   
 This process is very tightly regulated at the level of transcription.  Several 
transcription factors are involved in maintaining the B cell phenotype, while others are 
involved in progression to and maintenance of the plasma cell phenotype.  Most of these 
transcriptional regulators work in a mutually exclusive manner, meaning that a factor 
responsible for maintaining the B cell phenotype is repressed during further development 
to the plasma cell state (236). 
  Immature B cell
arrowBone m
 
Spleen
Marginal zone B cell
Secondary lymphoid organs 
Plasma cell ell 
ell 
Follicular B c
Germinal center B cell Memory B c
 
Figure 1.  Stages of B cell differentiation and development.  B cell to plasma cell 
differentiation occurs in a temporal and compartmentalized manner.   Immature B cells 
exit the bone marrow for further differentiation in  the spleen.  In the spleen, they become 
marginal zone B cells, moving to the secondary lymphoid organs for further 
development.  It is here that follicular B cells, germinal center B cells, and memory B 
cells further differentiate to plasma cells. 
3 
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Inducers of plasma cell differentiation 
 Treatment of B cells with cytokines stimulates the differentiation process.  In both 
murine primary B cells (223) and BCL1 lymphoma cells (263), interleukin (IL)-2 and IL-
5 co-stimulation differentiate B cells to plasma cells (164, 223, 263), as demonstrated by 
increases in PRDI-BF1/Blimp-1 and J chain mRNA (223) and a corresponding increase 
of Ig-secreting cells measured (118, 223).  The effects of IL-2 and IL-5 in the murine 
system are mimicked by IL-6 in human cells.  Human CESS cells stimulated with IL-6 
differentiate to plasma cells, with an increase in Ig secretion (173, 295) and PRDI-
BF1/Blimp-1 levels (202) and concomitant decrease in B cell markers, like class II major 
histocompatability complex (MHC) (173).  In some cases, IL-6 requires an additional 
stimulus to act as a differentiation factor, such as CD40 ligation (25) or IL-2 stimulation 
(242).   
 Treatment of both murine and human B cells with IL-21 induces plasma cell 
differentiation (62, 192).  In murine B cells, co-treatment with the B cell receptor (BCR) 
cross-linker anti-IgM not only induced B cell proliferation, but also induced expression 
of the plasma cell markers Syndecan-1 and surface Ig and decreased expression of MHC 
class II (192).  This correlated with an increase in PRDI-BF1/Blimp-1 mRNA and a 
decrease in BSAP/Pax5 mRNA expression.  IL-21 treatment either in the presence or 
absence of anti-IgM crosslinking of the BCR, induced Blimp-1 protein expression in 
murine cells (192).  In human B cells, the same effect is achieved by a combination of IL-
21, CD40 ligation, and cross-linking of the BCR with anti-IgM.  Cell cycle analysis 
demonstrated the majority of plasma cells were not actively cycling, indicating they were 
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terminally differentiated.  They were also able to secrete Ig, a hallmark of plasma cells 
(62, 192). 
B cell receptor cross-linking 
 When immature B cells leave the bone marrow (BM), they must undergo 
selection to become a mature B cell or they die (154).  This process is regulated by the 
BCR.  The majority of surviving immature BM B cells become mature B cells of the 
follicular or mantle zone cell subtypes.  Follicular B cells are resting, long-lived B cells 
with a half-life of approximately 4.5 months.  Working with T cells, they are important in 
the adaptive immune response (86).  Mantle zone B cells are readily able to detect foreign 
antigen, as they are localized to the marginal sinus region of the spleen that filters blood 
(149).  Upon encountering antigen, they respond rapidly by proliferating rapidly and 
differentiating to plasma cells, independent of T cell involvement (187, 200).  These 
plasma cells generate low affinity antibodies and are likely able to mount a first line of 
defense against foreign pathogens, allowing time for follicular B cells to coordinate with 
T cells to mount a high affinity antibody response (257).   
 BCR signaling plays an important role in the development of an immature BM B 
cell to a mature B cell.  BCRs themselves lack intrinsic cell signaling ability, pairing with 
both Ig-α and Ig-β to form the BCR complex.  Antigen binding to a BCR results in cross-
linking of multiple BCRs, leading to the formation of intracellular signaling complexes 
responsible for different cellular outcomes like proliferation, differentiation, and survival 
(257).  During early B cell development in the BM, the BCR only acts as a scaffold for 
intracellular signaling complexes, as truncation of the antigen receptor or targeting of Ig-
α/β to the membrane do not hinder development past the pre-B stage of development (7, 
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231).  However, as B cells transition from immature to mature B cells, termed transitional 
B cell maturation, the role of the BCR becomes important (257).   
 Immature and mature B cells exhibit different responses to BCR stimulation.  
This may in part be explainable by how BCR signaling works at the cell membrane.  In 
resting B cells, the majority of BCR complexes are located outside lipid rafts.  However, 
upon antigen stimulation, these complexes localize inside lipid rafts, activating other 
BCRs in an antigen-independent manner and amplifying the antigen response.  Many Src 
family kinase members like Lyn, Fyn, Blk, and Lck are localized to lipid rafts, which 
puts them near BCR complexes upon antigen stimulation, allowing for the rapid 
phosphorylation of immune receptor tyrosine-based activation motifs (ITAM) on Ig-α 
and Ig-β (257).  Mutating ITAMs on Ig-α and Ig-β blocks B cell development in the bone 
marrow (148, 258).  Some of the Src family kinase members do not play an essential role 
in BCR activation, such as Blk and Fyn (240, 255), while loss of Lyn results in reduced 
numbers of transitional B cells (2, 35).  Phosphorylated ITAMs recruit the cytoplasmic 
Syk/ZAP-70 kinase family member Syk, which then initiates the intracellular BCR 
response (264, 265).   
 ITAM activation results in recruitment of the adaptor molecules B cell linker 
(BLNK) and B cell adaptor for phosphoinositide 3-kinase (BCAP), which act as scaffolds 
for more signaling molecules.  BLNK and BCAP both appear to be important in the 
transitional B cell stage of development, as studies with knock-out mice have shown 
(110, 194, 287, 290).  When BLNK is absent, differentiation of immature B cells is 
delayed (287).  BLNK and BCAP activate phospholipase Cγ2 (PLCγ2) signaling acting 
through separate pathways.  BLNK binds PLCγ2 (103) as well as Btk (288), which then 
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allows for further activation of PLCγ2 (67).  Syk and Btk phosphorylate BCAP, allowing 
it to bind phosphoinositide 3-kinase (PI3K) (10, 186), which leads to the phosphorylation 
of more downstream targets, leading to activation of PLCγ2 (250).  Activation of PLCγ2 
leads to the production of diacylglycerol (DAG) and inositol-1,4,5-triphosphate (IP3), 
which activates a number of downstream signaling pathways responsible for the differing 
outcomes of BCR signaling (257). 
 In addition to proximal signaling events, expression of surface molecules on B 
cells can modulate outcomes during transitional B cell development.  The tyrosine 
phosphatase CD45 may dephosphorylate the inhibitory tyrosine on Src family kinases, 
thereby lowering the threshold for BCR-mediated B cell activation (42, 148).  CD19 also 
positively regulates BCR signaling through PI3K and its loss or overexpression affect 
transitional B cell development (60, 190, 298).   
 BCR-mediated signaling is an important part of transitional B cell development.  
However, the differential response of immature and mature B cells to BCR activation 
suggests the signaling pathways necessary for further development are expressed in a 
temporal manner (257).  To elucidate what is occurring in B cells in vivo, numerous in 
vitro studies have been done using anti-Ig cross-linking to stimulate the BCR.  Anti-IgM 
cross-linking of the BCR of an immature B cell in the absence of co-stimulatory 
molecules induces growth arrest or apoptosis (89).  The WEHI 231 immature B cell line 
undergoes growth arrest and/or apoptosis when treated with anti-IgM (12, 87), which 
may be due to defects in BCR signaling at multiple steps of the pathway.  It has been 
shown transitional B cells contain half the membrane cholesterol of mature B cells (113).  
Studies in immature B cells have demonstrated the inability of BCRs to localize to lipid 
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rafts (39, 243), limiting their access to adapter molecules necessary for further BCR 
signaling cascades.  When WEHI-231 B cells are co-stimulated by CD40 ligation, they 
survive, partly due to the upregulation of the anti-apoptotic Bcl-2 family member A1 
(122).  In murine primary B cells, survival conferred by IL-4 and anti-IgM co-treatment 
is mediated by upregulation of another anti-apoptotic member of the Bcl-2 family, Bcl-xL 
(284).  Much of the work detailing BCR activation and consequent signaling cascades 
have been done in vitro.  These studies have recently been extended to primary B cells 
isolated from normal donors, which have had comparable results and have been able to 
further elucidate the kinetics of BCR-mediated signaling following anti-IgM cross-
linking (102). 
Transcription factors involved in plasma cell differentiation 
Positive regulatory domain I binding factor 1 (PRDI-BF1)  
 The positive regulatory domain I binding factor 1 (PRDI-BF1) was originally 
found to specifically bind the interferon beta (IFN-β) promoter and suppress IFN-β 
transcription following viral induction (116).  PRDI-BF1/Blimp-1, a zinc-finger 
containing-protein (116), is induced by IL-2 and IL-5 in murine cell lines (263) and by 
IL-6 in human cell lines (202).  IL-21 is also able to induce PRDI-BF1/Blimp-1 
expression (192).  Because PRDI-BF1/Blimp-1 is able to drive the differentiation of B 
cells to immunoglobulin-secreting plasma cells, it has been termed the master regulator 
of plasma cell differentiation (263). 
 PRDI-BF1/Blimp-1 belongs to the PR (PRDI-BF1 and RIZ1) domain family, a 
small family of transcription factors involved in cell differentiation and tumorigenesis.  
Family members include RIZ1 (PRDM2) (27), MDS1-EVI1 (PRDM3) (66), PFM1/SC-1 
 (PRDM4) (38, 291), and MEL1/PFM13 (PRDM16) (168).  Similar to several of its 
fellow PR domain family members (66, 143, 286), the PRDM1 gene expresses two 
different products, the full-length PRDI-BF1α (hereafter referred to as PRDI-BF1) and 
PRDI-BF1β, characterized by a truncated PR domain (figure 2).  PRDI-BF1β is the 
product of alternative transcription initiation using an internal promoter of the PRDM1 
gene.  PRDI-BF1 is a transcriptional repressor, while PRDI-BF1β binds DNA but lacks 
transcriptional repression activity (80).  PRDI-BF1β mRNA expression is elevated in 
myeloma cell lines, suggesting the oncogenic potential of this gene (80).   
 
 
 
 
 
 
 
 
Pro Zn fingers Acidic PR Acidic 
 
Pro Zn fingers Acidic ∆PR 
 
 
Figure 2.  The PRDM1 gene expresses two different products.  Either full length 
PRDI-BF1α or the truncated PRDI-BF1β form are transcribed.  PRDI-BF1β is the result 
of alternative transcription initiation using an internal promoter.  PRDI-BF1β has a 
truncated PR domain and only one acidic domain.   
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 PRDI-BF1/Blimp-1 is able to directly repress several downstream targets 
involved in cell proliferation or maintenance of the B cell phenotype, thereby allowing a 
B cell to differentiate to a plasma cell.  Direct targets include c-myc (140), BSAP/Pax5 
(137), Spi-B (229), Id3 (229), and CIITA (74, 202) (figure 3).  Mechanisms for how 
PRDI-BF1/Blimp-1 exerts is repressive activity include recruitment of histone 
deacetylase activity (296) or histone methyltransferase activity to target promoters (81).  
Studies using c-myc as a target promoter demonstrated PRDI-BF1/Blimp-1 and HDAC2 
associate in vivo and are able to bind the c-myc promoter as a complex.  PRDI-
BF1/Blimp-1 is able to recruit HDAC activity to its target DNA because it contains two 
independent HDAC association domains, one in the proline-rich region and the other in a 
zinc-finger region (296).  The histone methyltransferase G9a is recruited to the IFN-β 
promoter by PRDI-BF1/Blimp-1 by binding its zinc finger domain and thereby silences 
IFN-β gene transcription (81).  Whether these mechanisms are involved in silencing of 
other targets, namely those specifically involved in B cell differentiation, is still 
unknown.   
 PRDI-BF1
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Figure 3.  PRDI-BF1 represses a number of downstream targets.  Direct targets of 
PRDI-BF1 are c-myc, BSAP, Spi-B, Id3, and CIITA promoter 3.  Repression by PRDI-
BF1 further affects the expression of additional targets, changing the global gene 
expression profile of B cells differentiating to plasma cells. 
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 PRDI-BF1/Blimp-1 is known to cause either differentiation or apoptosis of B 
cells.  The fate of a cell is determined by the stage of development a B cell finds itself in.  
The 5B1b and 3B3 sublines of the murine BCL1 B cell lymphoma cell line were used to 
demonstrate activated B cells were able to further differentiate, while immature and 
partially activated B cells underwent apoptosis upon IL-2 and IL-5 stimulation.  The 
activated 3B3 subline, which was derived from the 5B1b line, underwent differentiation 
upon interleukin stimulation, with a concomitant increase in plasma cell marker 
Syndecan expression and decrease in B cell marker CD19 expression.  In contrast, the 
partially activated 5B1b line demonstrated no change in Syndecan or CD19 expression.  
Transfection of Blimp-1 into these cells demonstrated Blimp-1 induced apoptosis in 
5B1b cells, but not 3B3 cells.  Similar results were found with forced expression of 
Blimp-1 in several B cell lines representing various stages of B cell development.  Blimp-
1 expression resulted in apoptosis of the pre-B 18-81, immature WEHI-231 and mature 
L10A cell lines.  Therefore, induced expression of PRDI-BF1/Blimp-1 determines the 
ultimate fate of a cell depending on its stage of B cell development. (164) 
 Recent studies using Prdm1 conditional knockout mice have demonstrated PRDI-
BF1/Blimp-1 is required for plasma cell development (237).  Its role in this process is 
accomplished by affecting several downstream targets.  It affects cell cycle and 
proliferation by targeting c-myc (140) and the anti-apoptotic gene A1 (119).  Upon 
introduction of Blimp-1 into immature WEHI-231 lymphoma cells, these markers 
decreased to levels below that of control cells.  These data agree with the normal short 
life span of plasma cells (119).  A1 gene expression levels are comparable to those of 
mature plasma cells and myeloma cells (254), indicating there is another mechanism for 
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how long-lived plasma cells are able to circumvent apoptosis.  PRDI-BF1/Blimp-1 is also 
responsible for upregulating genes involved in the plasma cell phenotype, namely those 
involved in Ig secretion.  These include Ig heavy and light chain genes, J chain (263) and 
X-box binding protein (XBP) (229).  Finally, PRDI-BF1/Blimp-1 is also responsible for 
downregulating genes associated with maintainence of the B cell phenotype, such as 
BSAP/Pax5 (137, 267) and BCL-6 (229).   
Role of PRDI-BF1/Blimp-1 in development 
 Blimp-1 homologues play an important role in the embryogenesis of a number of 
organisms, including Drosophila, zebrafish, sea urchin, chick, and mouse.  Blimp-1 
activity is required for the development of the peripheral nervous system sense organs 
and tracheal system in Drosophila (180) and is a key mediator in the development of 
slow twitch muscle in zebrafish, acting downstream of Hedgehog signaling (9).  The 
zebrafish Blimp-1 homologue u-boot (ubo) specifies formation of the neural crest and 
sensory neuron progenitors in the zebrafish embryo (217).  In chick embryos, the cBlimp-
1 is expressed during development of limb buds, eyes, and brachial arches (82).  In sea 
urchin development, the Blimp-1 homologue krox is alternatively transcribed and each 
form is expressed in a temporal and spatial specific manner (146).  This is similar to what 
occurs during mouse embryogenesis (36).  For instance, in the mouse embryo, Blimp-1 
expression appears as early as day 7 in the anterior endoderm and mesoderm head 
regions.  Expression at day 8 is restricted to the developing foregut and primordial germ 
cells.  During organogenesis, Blimp-1 expression is found in developing bone, teeth, and 
hands, with expression decreasing as development is completed (36).   
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Direct targets of PRDI-BF1/Blimp-1 
B cell-lineage-specific activator protein (BSAP) 
B cell-lineage-specific activator protein (BSAP), also known as the murine 
homologue Pax5 (paired box protein 5), is expressed only in B cells.  It both initiates 
commitment to the B cell lineage and maintains the B cell phenotype (165, 176) and is a 
direct target of PRDI-BF1/Blimp-1 (137).  BSAP/Pax5 is responsible for activating the 
Rag-mediated VH-to-DJH recombination of IgH (297) and Pax5-/- B cells have severely 
impaired VH gene segments, thereby demonstrating a requirement for BSAP/Pax5 
expression in pre-B cell development (266).  Pro-B cells can differentiate into other cell 
types upon cytokine-induction when BSAP/Pax5 expression is absent (181).  BSAP/Pax5 
acts upstream of genes important to the identity of B cells, namely CD19 and B cell 
linker (BLNK) (98) and when BSAP/Pax5 is deleted from B cells, gene expression of 
these downstream targets is downregulated.  Impaired BCR signaling occurs in Pax5-/- B 
cells, which is a reflection of decreased Blnk expression (98).   
Downregulation of BSAP/Pax5 results in the loss of the B cell phenotype and a 
transition to the plasma cell state.  This was seen by the decreased expression of BCR 
signaling and elevated levels of secreted IgM in the supernatant, both characteristics of a 
plasma cell phenotype (176).  Genes repressed by BSAP/Pax5 have recently been shown 
to be re-expressed in plasma cells, demonstrating the importance of BSAP/Pax5 in the 
plasma cell differentiation process (51) as repression of BSAP/Pax5 allows for 
differentiation to a plasma cell (137).  BSAP/Pax5 represses X-box binding protein 1 
(XBP), a transcription factor shown to be required for plasma cell differentiation (209).  
Inhibiting XBP is one mechanism by which BSAP is able to inhibit differentiation to a 
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plasma cell (210).  However, loss of BSAP expression does not mean PRDI-BF1 
expression is automatically induced (98).  This indicates other factors are also important 
in maintaining the B cell phenotype and preventing the differentiation to a plasma cell. 
Class II transactivator (CIITA) 
 Products of MHC class II genes play an integral role in immune responses.  MHC 
class II molecules present exogenous peptides to CD4+ T cells, thereby initiating the 
humoral immune response.  They are primarily expressed in antigen presenting cells 
(APCs), such as dendritic cells, B cells, and macrophages (269), but have also been 
shown to be expressed in cells of a non-hematopoietic origin (130).  MHC class II 
transactivator (CIITA) is the master regulator of MHC class II transcription.  CIITA is 
constitutively expressed in B cells and dendritic cells and is also induced by IFN-β in 
some systems (130).   
The human CIITA gene, MHC2TA, is transcriptionally regulated by four 
independent promoters, which each transcribe a unique first exon (figure 4).  Promoter I 
is active in dendritic cells, while promoter III is active in B cells.  Promoter IV is the 
IFN-β-inducible promoter.  The exact function of promoter II has yet to be elucidated 
(170).  Although promoter III was first shown to be active and functional in B cells, 
further study has demonstrated it to also be used in activated T cells (97, 281), monocytes 
(99), and dendritic cells (124, 130).   
 Expression of the gene encoding CIITA, MHC2TA, is silenced during the 
differentiation from a B cell to a plasma cell (220, 239).  As PRDI-BF1/Blimp-1 
expression increases during differentiation to a plasma cell, expression of CIITA 
promoter III decreases (202).  Additionally, in vivo footprinting of the CIITA promoter 
 III in plasma cells demonstrates lack of factor binding, meaning CIITA promoter III is 
bare (75, 239).  CIITA promoter III is a direct target of PRDI-BF1 repression (74, 202).  
PRDI-BF1/Blimp-1 binds CIITA promoter III at a site in the proximal promoter region 
(74, 202).  However, no interaction with this site is seen in plasma cells (75), because the 
promoter is bare in these cells.  PRDI-BF1/Blimp-1 has also recently been shown to 
repress CIITA promoter IV in lymphoid lineage cells (37).   
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Figure 4.  Expression of CIITA gene expression is regulated by four independent 
promoters.  Each promoter transcribes a unique exon 1, which occurs in a cell-type 
specific manner.  Promoter IV is IFN-γ inducible. 
 
 
c-Myc 
 c-Myc plays an important role in the growth, proliferation, and apoptosis of cells 
(40, 179, 224) and its dysregulation plays an important role in the onset of many different 
types of cancers, including B cell malignancies (127, 179).  c-Myc is a member of the 
helix-loop-helix/leucine zipper family of transcription factors (18).  It is an important 
factor in normal B cell differentiation, with high expression in the pro-B and pre-B stages 
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of development and lower expression in immature B cells which are in more of a resting 
stage of development.  Levels of c-myc increase during antigen-induced proliferation of 
mature B cells (125, 163). 
 c-Myc is one of the five direct downstream targets of PRDI-BF1/Blimp-1.  The c-
myc promoter contains a PRDI-BF1/Blimp-1 binding site, which when occupied 
represses c-myc promoter activity.  These data implicated c-myc as a direct target of 
PRDI-BF1/Blimp-1 (140).  When BCL1 cells are induced to differentiate by IL-2 and IL-
5 stimulation, PRDI-BF1/Blimp-1 mRNA levels are induced while c-myc protein 
expression is decreased (140).  Ectopic expression of c-myc in BCL1 cells blocked 
differentiation of these cells, as demonstrated by the low levels of secreted IgM and 
unchanged levels of Syndecan-1 on the cell surface.  These cells also continued 
proliferating (138).  However, repression of c-myc transcription by a dominant negative 
form of c-myc did inhibit cell proliferation, but was not sufficient to cause differentiation 
of BCL1 cells.  These data pointed to regulation of additional PRDI-BF1/Blimp-1 target 
genes as a requirement for plasma cell differentiation (138).    
Spi-B and Id3 
 PRDI-BF1/Blimp-1 was found to directly bind Spi-B and Id3 by gel shift assays 
and chromatin immunoprecipation assays, corroborating microarray data (229).  The Ets 
family member Spi-B and inhibitor of differentiaton 3 (Id3) are both involved in 
regulating BCR signaling (70, 193, 244).  Spi-B is expressed at all stages of B cell 
development (226) and has also been shown to be expressed in normal plasma cells as 
well as those isolated from myeloma patients, but not in myeloma cell lines (172).  Spi-B 
acts with PU.1 to regulate proper BCR signaling downstream of Syk phosphorylation 
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(70) and also affects Btk transcription (171).  Id3 is required for proliferation of B cells 
following BCR cross-linking, but is dispensable for normal B cell development, as has 
been shown using Id3 knockout mice (193).  Both mRNA and protein levels are 
increased in WEHI 231 B cells stimulated with the BCR cross-linker anti-IgM, with 
corresponding growth arrest (88).  This is due to transcriptional regulation of the Id3 
promoter by anti-IgM in these cells (135).  Id3 is a direct downstream target of PRDI-
BF1, but the authors never studied PRDI-BF1 expression levels in these experiments.   
X box binding protein 1 (XBP-1) 
 X box binding protein 1, or XBP, is a transcriptional activator belonging to the 
CREB/ATF family.  It is required for differentiation to a plasma cell and is expressed at 
high levels in plasma cells (104, 210).  Expression of PRDI-BF1 is required for the 
induction of XBP expression (237).  This occurs by the direct repression of BSAP/Pax5 
by PRDI-BF1, which leads to the upregulation of XBP (137).  Splicing of XBP mRNA 
generates a more stable form of XBP, termed XBPS, which plays an important role in the 
secretory process of plasma cells (105).   
Plasma cells and immunoglobulin secretion 
 A hallmark of plasma cells is their ability to secrete immunoglobulins (236).  
PRDI-BF1/Blimp-1 and XBP have separate and distinct roles in this process (232).  
Microarray experiments were done using prdm1-deficient and xbp-deficient mice.  Using 
lipopolysaccharide (LPS) treatment to induce plasma cell differentiation in the splenic B 
cells of these mice, XBP1 mRNA was shown to be induced in wild-type, but not prdm1-
deficient mice, while PRDM1 mRNA expression was induced equally in wild-type and 
xbp-deficient mice.  These data were consistent with previous findings that PRDI-
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BF1/Blimp-1 acts upstream of XBP (229, 237).  This work showed many genes involved 
in the secretory pathway were dependent on both PRDI-BF1 and XBP.  Expression of the 
sdc1 gene, which encodes the plasma cell marker Syndecan-1, was dependent only on 
PRDI-BF1 expression.  PRDI-BF1 was also required for Ig gene induction.  Therefore, 
PRDI-BF1 is responsible for plasma cell gene expression, while XBP, acting downstream 
of PRDI-BF1, is responsible for coordinating the changes in cell structure and function as 
leading to the secretory phenotype of plasma cells (232). 
 XBP is involved in the unfolded protein response (UPR) in plasma cells.  The 
endoplasmic reticulum (ER) is the site of protein synthesis and folding, which require an 
optimal mix of factors such as ATP, Ca2+, and an environment conducive to disulphide-
bond formation.  Because of this, the ER environment can be disturbed by stresses 
affecting cellular energy levels, the redox state, and Ca2+ concentrations.  Upon ER 
stress, unfolded proteins accumulate in the ER, which results in the cell responding with 
the UPR (249).  During the UPR, the ER folds and translocates proteins, protein synthesis 
decreases, and cell cycle arrest and apoptosis occur (225).  While the endoplasmic 
reticulum is involved in plasma cell differentiation, decreased protein synthesis is not.  
Therefore, it has been suggested that there is a “physiologic” UPR in addition to the well-
defined stress-induced UPR.  And, it is this “physiologic” UPR that plasma cells use (72, 
232).   
 Activating transcription factor 6 (ATF-6) (294), IL-4 (105), and Blimp-1-
dependent repression of BSAP (137) are all responsible for inducing XBP mRNA.  
Studies using xbp-deficient mouse B cells induced to differentiate and human Raji B cells 
expressing the transcriptionally active, processed form of XBP demonstrated XBP 
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involvement in almost every aspect of the secretory process.  XBP regulated genes 
responsible for targeting proteins to the endoplasmic reticulum (ER), translocating them 
across the ER membrane, folding of ER proteins, degradation of misfolded proteins, 
protein glycosylation, trafficking between the ER and the Golgi, trafficking in the 
endosomal pathway, and targeting of secretory vesicles to the plasma membrane (232).  
XBP is also responsible for increasing the mass of mitochondria and nucleus, size of the 
ER, and overall size of the cell (232). 
B-cell lymphoma 6 (BCL-6) 
 B-cell lymphoma 6, or BCL-6, was discovered as a gene that is translocated in 
some non-Hodgkin’s lymphomas (8, 292).  It is required for germinal center (GC) 
formation (52) and is highly expressed in these cells (33).  BCL-6 represses PRDI-BF1 
expression (234, 262) by inhibiting AP-1-dependent activation (271), by blocking 
STAT3-dependent gene transcription (211), and by direct repression (235).  By 
repressing PRDI-BF1/Blimp-1 expression, BCL-6 allows the GC reaction to continue 
before plasma cell differentiation occurs (234).  However, microarray analysis shows 
PRDI-BF1/Blimp-1 is also able to repress BCL-6 expression (229).   
Interferon regulatory factor family 
 Expression of interferon regulatory factor (IRF) family members is primarily 
restricted to lymphoid cells (57, 159).  IRF-4 is a member of the IRF family of 
transcriptional regulators.  IRF-4 has been shown to be required for plasma cell 
differentiation (28) and is expressed by both plasma cells and GC B cells expressing 
PRDI-BF1/Blimp-1 (5, 64).  It is also required for the initial proliferative burst of 
activated B cells (166).  IRF-4 has been proposed to be responsible for preparing B cells 
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for the differentiation process by inducing this proliferative burst which precedes 
terminal differentiation (236).  This is based on the observation that loss of Mitf, a factor 
which represses IRF-4, leads to the formation of plasma cells and a concomitant increase 
in IRF-4 expression (139). 
 IRF-4 is able to bind IFN-stimulated response elements and repress IFN-
stimulated genes on its own (289).  In the presence of the Ets family member PU.1, IRF-4 
is able to activate the CD20 promoter and the Ig κ 3’ enhancer (57, 94, 203), while IRF-4 
complexed with PU.1 can downregulate CD68 expression in lymphoid cells (183).  IRF-4 
can interact with BCL-6 (79) as well as PRDI-BF1/Blimp-1 (78).  Its interaction with 
PRDI-BF1/Blimp-1 represses CD23b (78).   
 IRF-8 is another member of the IRF family, which has recently been shown to 
activate PRDI-BF1/Blimp-1 in murine myeloid progenitor cells (252).  IRF-8 is 
constitutively expressed in macrophages, B cells, T cells, and dendritic cells (56, 152, 
174, 221, 259, 276, 277).  A recent study demonstrated insertion of proviral elements at 
the IRF-8 locus in mice with primarily B cell lymphomas or plasmacytomas (153), 
indicating IRF-8 might play a role in the proliferation of B cell lymphomas.  IRF-8 
expression was found to be high in B cells, but is decreased in plasma cells (128).   In GC 
B cells, BCL-6 was shown to be a target of activation by IRF-8 (128).  Therefore, IRF 
family members appear to play an important role in B cell development and 
differentiation.   
PU.1 
 PU.1 is a transcription factor belonging to the Ets family and is an important 
regulator of B cell development (83).  PU.1 regulates genes expressed at both early and 
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late stages of B cell development (49, 161, 270, 293), but is not expressed in plasma cells 
(172, 198).  Mice lacking PU.1 are deficient for both B cells and macrophages, 
demonstrating the importance of PU.1 in B cell development (162, 227).  PU.1 regulates 
expression of the IL-7Rα, which is necessary for pro-B cell differentiation and survival 
signals conferred by IL-7 (49).  This regulation occurs in a graded manner.  If PU.1 
expression is low, B cell development occurs, with concomitant increases in IL-7Rα gene 
expression (49, 50).  When PU.1 expression is high, B cell development is repressed and 
macrophage differentiation is induced (50).   
 Ets family members can complex with other transcription factors or other family 
members to regulate gene expression (134).  They can interact with AP-1, Sp1, BSAP, 
NF-κB (134), and IRF family members (61, 157) in a cell-type specific manner.  In 
hematopoietic cells, PU.1 can interact with IRF family members to regulate gene 
expression (183, 188, 270).  For example, IRF-8 has been shown to regulate gene 
expression of RANTES in cooperation with IRF-1, PU.1, and NF-κB at an NF-κB site in 
murine macrophages (142).   
B cell lymphomas 
 Lymphoid malignancies, such as lymphomas and leukemias, can occur when the 
normal process of B cell differentiation is disrupted.  Gene expression profiling has 
recently demonstrated the similarity between lymphoid malignancies and various stages 
of normal B cell development (46, 230, 233, 238).  Diffuse large B-cell lymphomas 
(DLBCL) are further classified as either germinal center B-cell-like (GC) DLBCL or 
activated B-cell-like (ABC) DLBCL.  GC DLBCLs have a gene expression profile 
comparable to that of normal GC B cells (1, 214, 215) and appear to be fixed at the GC 
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stage of B cell differentiation (230).  Unlike GC DLBCLs, ABC DLBCLs have a 
molecular profile analogous to activated peripheral B cells (1, 214, 215).  They resemble 
pre-plasma cells in terms of their increased expression of Ig, X-box binding protein 
1(XBP), IRF-4, and PRDI-BF1/Blimp-1 (195, 215, 230, 251) while their expression of 
BCL-6 is lower (215, 230).  Burkitt’s lymphomas also express GC B cell genes, as do 
follicular lymphomas (230).  Burkitt’s lymphomas can be distinguished from DLBCL by 
high levels of c-myc target genes and a subgroup of GC B cell genes as well as low levels 
of MHC class I genes and NF-κB target genes (46).  Distinguishing the molecular 
profiles of lymphomas is important, as the specific genetic alterations that occur disrupt 
normal B cell differentiation by affecting their progression through the cell cycle, their 
ability to undergo apoptosis, and their ability to differentiate normally (230).   
Role of PRDI-BF1 in lymphoma and myeloma cells 
 PRDI-BF1/Blimp-1 has long been demonstrated to be expressed in plasma cells, 
but not in B cells (172).  Recent findings demonstrate expression of PRDI-BF1/Blimp-1 
in a subset of lymphoma cells, namely GC B cells which are also positive for plasma cell 
markers (32).  Diffuse large B cell lymphoma (DLBCL) can be divided into several 
subtypes based on recent molecular profiling data.  These subtypes are representative of 
the origins from the different stages of B cell differentiation.  Germinal center B cell-like 
(GCB) DLBCL is thought to derive from GC centroblasts, while activated B cell-like 
(ABC) DLBCL resembles the phenotype of a small group of GC cells undergoing 
differentiation to a plasma cell (1, 230). 
 However, even though a subset of ABC-DLBCLs expresses the PRDM1 gene, it 
appears to be a functionally inactive form, as protein levels are not expressed in these 
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cells (24, 69, 195, 251).  It has been proposed that lack of functional PRDI-BF1/Blimp-1 
leads to inhibition of differentiation in these cells, forcing these GC B cells to remain in 
an active, proliferative state, eventually leading to the development of DLBCL (251).  
Mutational analysis of the PRDM1 gene in both DLBCL cell lines and patients 
demonstrated genetic alterations, leading to a lack of protein expression in these cells.  Of 
35 patient samples studied, 8 had genetic alterations such as point mutations and 
frameshift mutations, all leading to premature translation termination and production of a 
non-functional form of PRDI-BF1/Blimp-1 (251).  Pasqualucci et al. did a similar study 
of the PRDM1 gene, but looked at mutations in both ABC-DLBCL and GC-DLBCL 
patients.  No PRDM1 gene mutations were found in GC-DLBCL patient samples, but 
24% of ABC-DLBCL patient samples had genetic alterations (195).  It appears PRDM1 
gene inactivation by mutation in some DLBCL patients contributes to lymphomagenesis 
by inhibiting the normal differentiation process of GC B cells (195, 251).  The loss of 
functional PRDI-BF1/Blimp-1 in some DLBCL cases suggests PRDM1 acts as a tumor 
suppressor gene in a small subset of lymphomas (195, 251). 
 The expression of PRDI-BF1/Blimp-1 in myeloma cells has been widely reported 
(21, 74, 80, 172).  However, a recent report by Borson et al. shows PRDM1 gene 
expression is found in B cells derived from myeloma patients, but not in those from 
normal, healthy donors (21).  Genetic alterations of the PRDM1 gene were not studied 
(21), but these findings indicate PRDI-BF1/Blimp-1 may be important to the pathology 
of lymphomas and myelomas.   
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Drug resistance in multiple myeloma 
 
 Multiple myeloma is a fatal plasma cell malignancy characterized by the 
accumulation of latent plasma cells in the bone marrow (84).  These cancerous cells resist 
apoptosis and are characterized by a low-proliferative index (268).  The disease course of 
patients with myeloma typically includes the emergence of drug-resistant plasma cells 
(76), a phenotype termed multidrug resistance (MDR).  Following an initial response to 
treatment, many patients invariably become refractory to treatment.  Therefore, it 
becomes important to find new drugs which can overcome this phenotype and still be 
effective in patients. 
 Several mechanisms of MDR have been well elucidated.  These include decreased 
uptake of drugs, due to the presence of drug transporters; cellular mechanisms which 
diminish the capacity of drugs to kill cells, such as cell cycle alterations, DNA damage 
repair mechanisms, and altered drug metabolism; and, increased energy-dependent efflux 
of drugs that enter the plasma membrane by diffusion (248).  Drug resistance in myeloma 
cells is also conferred by interaction of myeloma cells with extracellular matrix 
components of the bone marrow (45).   
 Activating Ras mutations have been shown to be involved with chemoresistance 
in melanoma cells (107) and ovarian cancer cells (96).  They have also been 
demonstrated to be important in myeloma cells.  ANBL6 myeloma cells transfected with 
mutated N- or K-Ras were shown to be more resistant to dexamethasone, doxorubicin, 
and melphalan than control cells (216).  Recently, the same ANBL-6 transfectants were 
shown to have enhanced binding to both the extracellular matrix component fibronectin 
and bone marrow stromal cells (BMSC), which was found to be mediated by increased 
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levels of cyclooxygenase (cox)-2 in fibronectin-adhered cells.  The mechanism for 
enhanced binding to the BMSCs remains to be elucidated (95).  Regardless, increased 
cox-2 levels in ANBL6 cells expressing activated N- and K-Ras are correlated with 
increased resistance to treatment with melphalan (95).  Although the exact mechanism by 
which activated Ras protects cancer cells from apoptosis is still unknown, activating 
mutations of the Ras oncogene play an important role in protecting myeloma cells from 
chemotherapy-induced apoptosis.   
Apoptosis and role of Bcl-xL
 Apoptosis, or programmed cell death, is a finely tuned cascade of events leading 
to the eventual death of cells.  Apoptosis plays an important role in the daily self-renewal 
of organs and tissues in the body.  As new cells are produced, a homeostatic balance is 
maintained by older cells dying in an ordered fashion (207, 208).  The apoptotic process 
contrasts with necrosis, in that there are no inflammatory reactions or tissue scarring 
(207).  When apoptosis is deregulated, disease states such as cancer occur and can be 
maintained due to defects in the apoptotic machinery.   
 The Bcl-2 family of proteins plays an important role in regulating cell death.  
Several family members are pro-apoptotic (Bax, Bok, Bid), while others have an anti-
apoptotic role in cells (Bcl-2, Bcl-xL, Mcl-1, Bfl-1/A1) (34).  Bcl-2 family members 
regulate apoptosis by either interacting with other family members (197) or by regulating 
ion-channel activity (207).  It is the ratio of pro- and anti-apoptotic Bcl-2 family members 
which determines the ultimate fate of a cell in response to an apoptotic signal (268).  
Anti-apoptotic family members are localized to the nuclear membrane, endoplasmic 
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reticulum, or mitochondrial outer membrane, while pro-apoptotic family members are 
generally found in the cytosol or associated with the cytoskeleton (77).   
 Bcl-xL expression is associated with chemoresistance in myeloma cells (261) and 
is expressed in normal plasma cells as well as myeloma cell lines and patient samples 
(205, 241).  IL-6, an essential cytokine to the growth and survival of myeloma cells, 
upregulated Bcl-xL protein levels in both patient samples and cell lines (205).  Studies 
using Bcl-xL transgenic mice demonstrate a nonmalignant plasma cell phenotype in both 
the bone marrow and lymphoid organs of these mice, whose incidence increased with the 
age of the animal (141).  However, when the Bcl-xL mice were crossed with c-myc 
transgenic mice, the plasma cell phenotype became one of malignancy with death from 
lymphoproliferative disorder at 5.5 weeks in 50% of the double-transgenic mice (141).  
These data provide a link between Bcl-xL and myeloma disease pathology.   
The role of the Ras oncogene in myeloma 
 The Ras proteins are members of a large superfamily of GTP-binding proteins, 
which are subdivided based on sequence homology.  Ras family members are involved in 
control of cell growth.  This family is comprised of 3 members, namely H-Ras, K-Ras, 
and N-Ras.  These members can be activated by mutation at codons 12, 13, and 61 (22).  
When Ras is activated, it is bound to GTP and able to interact with its downstream target 
enzyme (55).  When Ras is inactive, it is found in the GDP-bound form.  In the normal 
situation, the ratio of bound GTP to GDP controls the activity of Ras proteins (29).  This 
biological activity is controlled by a GDP/GTP cycle, which is regulated by GDP/GTP 
exchange and GTP hydrolysis.  GEFs, or guanine nucleotide exchange factors, regulate 
the exchange of GDP for GTP, while GAPs, or GTPase activating proteins, regulate 
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hydrolysis of GTP (29).  However, when Ras is mutated, the equilibrium of Ras-GTP to 
Ras-GDP is weighted in favor of the active, GTP-bound form.  GAPs are prevented from 
hydrolyzing the GTP on Ras, locking it in the active form (55).  This leads to constitutive 
activation of Ras proteins. 
 Members of the Ras family GTPases have a well-established role in oncogenesis 
(22).  Mutations of various Ras family members have been shown to be associated with 
various cancers (156), including multiple myeloma.  Numerous investigators have 
examined the frequency of Ras mutations in multiple myeloma, and have reported a 
correlation between activating Ras mutations and disease progression (15, 41, 144, 178, 
204, 206).  Activating mutations of N-Ras and K-Ras codons 12, 13, and 61 are involved 
in myeloma disease progression (15).   
Prenylation of the Ras oncoprotein 
 Ras proteins must undergo further post-translational modification upon being 
synthesized to become biologically active molecules.  Otherwise, Ras remains an 
inactive, cytosolic protein.  Ras proteins undergo protein prenylation to allow targeting to 
the plasma membrane, where they become active players in signaling cascades (55, 85, 
280).  The mevalonate pathway, also commonly recognized as the cholesterol 
biosynthetic pathway, is responsible for the production of cholesterol and nonsterol 
products (167).  It is also the pathway that plays an important role in protein prenylation 
reactions (see figure 5).  Two enzymes, farnesyltransferase (FTase) and 
geranylgeranyltransferase I (GGTase I), catalyze this prenyl posttranslational 
modification by transferring farnesyl or geranylgeranyl, respectively, to the cysteine of 
the carboxyl terminal CAAX box ((C=cysteine, A=aliphatic amino acid (leucine, 
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isoleucine, or valine), X=any amino acid)) (55, 106).  Following addition of the farnesyl 
or geranylgeranyl group to the cysteine residue, the three terminal amino acid residues 
(AAX) are cleaved in the endoplasmic reticulum by the endoprotease Rce1(191).  
Finally, the cysteine residue becomes carboxyl methylated (43, 65).  H-, N-, and K-Ras 
are all farnesylated.  When FTase is inhibited, K-Ras, but not N-Ras or H-Ras, becomes 
geranylgeranylated (133). 
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Figure 5.  The mevalonate pathway plays a role in generating prenylated proteins.  
Farnesyl or geranylgeranyl are transferred to the carboxyl terminal cysteine residue by 
either the enzyme farnesyl transferase or geranylgeranyl transferase, respectively.  
(adapted from (167)) 
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Figure 6.  Prenylation occurs on the carboxy terminal CAAX box.  Farnesyl and 
geranylgeranyl groups are transferred to the cysteine residue of the CAAX motif by 
either farnesyl or geranylgeranyl transferase, respectively.  The –AAX residue is cleaved 
in the endoplasmic reticulum (ER) by the enzyme Rce1 and the cysteine residue is 
modified by addition of a carboxy methyl group (OMe).  (adapted from (123)) 
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Downstream targets of Ras 
 Activated Ras is able to mediate signaling through a variety of downstream kinase 
pathways that regulate cell proliferation and survival (123).  These include the Raf-MEK-
MAPK (mitogen-activated protein kinase) and PI3K (phosphatidyl inositol-3 
kinase)/AKT pathways.  These pathways can be activated in response to a variety of 
growth factors (131).  However, activated Ras has been shown to act independently of  
the exogenous myeloma growth factor IL-6 in Ras-mutated ANBL6 cells (16, 17), while 
the parental ANBL6 cells are IL-6-dependent and stop growing when IL-6 is removed 
(108).  Therefore, mutated Ras confers a survival advantage to myeloma cells by 
activating signaling pathways responsible for cell growth and survival, independent of 
normal growth factors.   
 The Raf-MEK-MAPK pathway is one of the key signaling pathways downstream 
of Ras.  Raf is a serine-threonine protein kinase which binds Ras to become active (23, 
274).  Once active, Raf is able to initiate a cascade of phosphorylation events in 
downstream targets, which results in the phosphorylation of MAPK.  MAPK is now 
active and can translocate to the nucleus, activating transcription factors which regulate 
cell proliferation and apoptosis (20, 285).  In myeloma, MIP1-α was recently shown to be 
a downstream target of MAPK signaling in Ras mutated myeloma cells.  MIP1-α is an 
important survival and proliferation factor in myeloma cells as well as an important 
factor in myeloma-associated bone disease (158). 
 Myeloma growth-stimulating cytokines, such IL-6 (4, 115), activate signal 
transduction through the PI3K/AKT signaling pathway resulting in cell proliferation and 
survival (26, 117).  Activated Ras interacts directly with the PI3K catalytic subunit, 
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which leads to the activation of the serine-threonine kinase AKT (109, 212).  AKT is 
frequently activated in myeloma cells and correlates with disease activity (100).  
Inhibition of AKT resulted in decreased cell proliferation (260) and increased apoptosis 
(93).  Treatment with both the farnesyl transferase inhibitor lonafarnib and the 
proteasome inhibitor Bortezomib were shown to downregulate phospho-AKT and induce 
apoptosis (47).   
Inhibitors of protein prenylation 
 The high incidence of Ras mutations in cancers, which leads to the constitutive 
activation of Ras proteins, drove the development of pharmacologic inhibitors of Ras 
(123).  Non-selective agents which targeted the mevalonate pathway, such as the HMG 
CoA reducatase inhibitor lovastatin, were initially used to inhibit Ras prenylation.  
Unfortunately, patients treated with this drug developed dose-inhibiting side effects due 
to the nonspecific nature of this compound (256).  Therefore, inhibitors to other steps of  
the mevalonate pathway were developed to target protein prenylation of Ras.  Several 
classes of farnesyl transferase inhibitors (FTI) have been designed in recent years to 
target the biological function of Ras proteins.  Screening of libraries and natural products 
has yielded farnesyl diphosphate (FDP) analogues as one class of FTIs.  CAAX 
peptidomimetics are another class of FTIs which compete for farnesyl transferase binding 
by mimicking the carboxyl terminus CAAX motif of Ras and related proteins.  Some 
compounds share properties of both the CAAX box and farnesyl diphosphate and are 
known as bisubstrate analogues because they mimic a step in the mevalonate pathway.  A 
fourth class of FTIs are the nonpeptidomimetic inhibitors, which have been identified by 
random screening of compound libraries (55, 123). 
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 FTIs have been developed by pharmaceutical companies as potential anti-cancer 
agents.  Some of these include R115777 (tipifarnib), SCH66336 (lonafarnib), and BMS-
214662 (106).  In clinical trials, R115777 has been found to be effective against 
hematopoietic malignancies, like myeloma (3).  Geranylgeranyl transferase inhibitors 
have also been developed because when farnesylation of N- and K-Ras are blocked, they 
become alternatively geranylgeranylated.  However, attempting to use both together at 
doses required to block prenylation are not effective due to toxicity issues (147).  
Therefore, targeting activating mutations of Ras in myeloma cells with prenyltransferase 
inhibitors is an important area of study. 
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Chapter Two 
Transcriptional regulation of PRDI-BF1/Blimp-1 in lymphoma and myeloma cells 
 
Introduction 
 The positive regulatory domain I binding factor 1 (PRDI-BF1) was originally 
found to specifically bind the interferon beta (IFN-β) promoter and suppress IFN-β 
transcription following viral induction (116).  Blimp-1, the murine homologue of PRDI-
BF1, was originally described by Turner et al. as a transcription factor that could induce 
the differentiation of B cells (263).  PRDI-BF1/Blimp-1 has since been found to be 
required for the differentiation of a B cell to a plasma cell (237).  During the 
differentiation of mature B cells to plasma cells, PRDI-BF1 represses multiple genes 
involved in maintaining the B cell phenotype and in maintaining cellular proliferation, 
such as CIITA (74, 202), c-myc (140), and BSAP (137).  Microarray studies have 
outlined the PRDI-BF1 repression profile and led to the identification of two additional 
direct targets, Spi-B and Id3 (229).  Additionally, PRDM1 has recently been linked to 
cellular stress and the unfolded protein response (54). 
Anti-IgM cross-linking of the B cell receptor has been reported in multiple studies 
to induce apoptosis in lymphoma (12, 30, 87, 112, 299). This response has been 
correlated with decreased levels of c-myc (140).  Inducing PRDI-BF1/Blimp-1 
expression in lymphoma cells with histone deacetylase inhibitors also decreased 
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expression of the downstream targets c-myc and BSAP (129).  More specifically, 
introduction of Blimp-1 into lymphoma cells can induce apoptosis, suggesting PRDI-BF1 
may be an important mediator of the anti-IgM and apoptotic response (119, 164).  
However, no direct link between expression of PRDI-BF1/Blimp-1 and anti-IgM 
mediated B cell receptor activation has been described. 
Recently, PRDI-BF1/Blimp-1 expression has been detected in some diffuse large 
B cell lymphomas (DLBCL) (69, 195, 251).  However, inactivating mutations were 
described indicating a potential tumor suppressor role for this gene (195, 251).  Similarly, 
proliferating myeloma cells and myeloma cell lines abundantly express the truncated 
PRDI-BF1 isoform, PRDI-BF1β, which has impaired function (80).  In addition, Borson 
et al. (21) suggest that PRDM1 expression is present in B cells isolated from myeloma 
patients while normal donors lack expression as expected. The mutation status of PRDM1 
in these myeloma derived B cells is unknown. Together these findings indicate PRDI-
BF1/Blimp-1 may be important to the pathology of various hematopoietic malignancies, 
including lymphoma.   
 Very little is known about how PRDI-BF1 expression is regulated.  Our data now 
demonstrate PRDM1 is regulated primarily at the level of transcription in both myeloma 
cells and in lymphoma cells stimulated by cross-linking of the B cell receptor.  B cell 
receptor stimulation leads to rapid increases in mRNA levels and promoter activity while 
mRNA stability is unchanged.  Using promoter deletion constructs and in vivo genomic 
footprinting, we demonstrate two regions of activation in the PRDM1 promoter and 
multiple in vivo protein-DNA interactions at the proximal promoter and at more distal 
activation regions in both lymphoma and myeloma cells.  Three of the detected 
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interactions occur in a cell-type specific manner and PU.1 binding is revealed to be 
functionally important for promoter activity in stimulated lymphoma cells.  These 
findings demonstrate the PRDM1 promoter is poised for rapid activation in lymphoma 
cells, which suggests inducing PRDI-BF1 expression in lymphoma cells may be a viable 
target to inhibit lymphoma progression. 
 
Results 
Expression of PRDM1 mRNA levels in lymphoma and myeloma cells 
 Most B cells lack detectable levels of PRDM1 until they commit to differentiate 
(5, 24, 32, 69).   As shown in figure 7, Burkitt’s lymphoma cell lines lack detectable 
levels of PRDM1 while myeloma cells have abundant PRDM1 expression.  Analysis of 
myeloma patient bone marrow samples show that compared to normal bone marrow, 
myeloma bone marrow expresses very high levels of PRDM1 mRNA. We next examined 
the effects of B cell receptor cross-linking on PRDM1 mRNA levels in CA46 Burkitt’s 
lymphoma cells.  Treatment with anti-IgM to cross-link the B cell receptor significantly 
increased PRDM1 mRNA levels approximately 8-fold above untreated controls (p<0.05) 
(figure 8A).  This induction strongly correlated with increased apoptosis, as measured by 
Annexin V staining (figure 8B). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.  PRDI-BF1 mRNA levels are elevated in myeloma cells versus lymphoma 
cells. A, Basal levels of PRDI-BF1 mRNA were determined in both lymphoma and 
myeloma cell lines by real-time RT-PCR.  Lymphoma cells have nearly undetectable 
mRNA, while myeloma cell lines have significant but variable levels.  PRDI-BF1 mRNA 
levels were normalized to GAPDH mRNA levels.  The data is representative of at least 
three experiments.  B, PRDI-BF1 mRNA levels are elevated in bone marrow samples 
derived from myeloma patients when compared to normal healthy donor samples.  NBM, 
normal bone marrow (Stratagene); N1 and N2, donors with other disease but without any 
evidence of bone marrow involvement (H. Lee Moffitt Cancer Center Tissue Bank); M1-
M5, myeloma patient bone marrow containing 53-76% plasma cells.  
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Figure 8.  Anti-IgM treatment induces PRDI-BF1 mRNA levels and apoptosis in 
CA46 lymphoma cells.  A, Treatment of CA46 lymphoma cells for 24 hours with 10 
µg/ml anti-IgM induces PRDI-BF1 mRNA levels significantly.  The mean of 3 
experiments is shown (p<0.05, Student’s t-test).  B, Treatment with anti-IgM for 24 hours 
induces apoptosis approximately 60% above the control in CA46 lymphoma cells, as 
assessed by Annexin V staining followed by FACS analysis.  The data is representative 
of 3 independent experiments. (Gray histogram, untreated control; black outlined 
histogram, treated cells) 
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PRDI-BF1 regulation occurs at the transcriptional level 
 As was shown in figure 7A, lymphoma cells do not have detectable levels of 
PRDM1 mRNA, while myeloma cells express very high levels.  Therefore, to determine 
the level at which PRDM1 regulation occurs, we examined basal levels of nascent RNA 
production in both lymphoma and myeloma cells.  Nascent RNAs, defined as those 
RNAs still in the process of being transcribed, are an accurate measure of endogenous 
transcriptional activity (283).  The nascent RNA were purified from nuclei after extensive 
washing to remove the released transcripts and quantified by real-time RT-PCR with 
specific primers directed to the 5’ end of the RNA transcript.  Levels of nascent RNA 
production in CA46 lymphoma cells are significantly lower (p<0.005) than that of U266 
myeloma cells (figure 9A).  Because anti-IgM stimulation significantly increases PRDM1 
mRNA levels (figure 8A), nascent RNA production in CA46 lymphoma cells stimulated 
with anti-IgM was examined.  Treatment of these cells for 1 hour with anti-IgM 
significantly increased production of PRDI-BF1 nascent RNA (p<0.05) (figure 9B).   
To further establish the transcriptional activation of PRDM1, we cloned 2618 
basepairs of the promoter (80) and examined the effect of B cell receptor stimulation on 
transcriptional activity (figure 9C).  A statistically significant increase in luciferase 
activity was observed 24 hours after stimulation.  This indicates that, at least in part, the 
transcription activation is mediated by elements within the 2618 bp promoter.  
Examination of PRDM1 mRNA stability did not reveal any changes upon anti-IgM 
treatment (figure 9D).  Together these data indicate regulation of PRDI-BF1 occurs 
primarily at the level of transcription. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.  PRDI-BF1 regulation occurs at the level of transcription. A, Relative levels 
of nascent RNA were determined by real-time RT-PCR for both CA46 lymphoma and 
U266 myeloma cells.  Levels in U266 myeloma cells are significantly higher than that of 
CA46 lymphoma cells (p<0.005, Student’s t-test).  B, In CA46 lymphoma cells treated 
with anti-IgM for 1 hour, relative levels of PRDI-BF1 nascent RNA increase significantly 
(p<0.05, Student’s t-test).  C, Anti-IgM treatment (24 hours) of transiently transfected 
CA46 cells with PRD 2618 shows a significant increase in luciferase activity (p<0.05, 
Student’s t-test).  D, Stability of PRDM1 mRNA is unchanged upon treatment with anti-
IgM.  CA46 cells were pre-treated for 1 hour with anti-IgM, followed by a time course 
with Actinomycin D to determine mRNA half-lives.  In all panels, data shown is the 
mean of at least 3 experiments.  
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Identification of regulatory regions in the PRDI-BF1 promoter 
 Because PRDI-BF1 is primarily regulated at the level of transcription, further 
examination of the PRDI-BF1 promoter is necessary to determine specific areas of 
regulation.  Using promoter deletion constructs, potential regulatory regions in the 
promoter were identified in both CA46 lymphoma and U266 myeloma cells.  As shown 
in figure 10A, strong promoter activity is detected in U266 myeloma cells with the 
proximal 521 bp promoter region as compared to the pGL3-basic control.  Two distal 
regions conferring additional activation were also detected.  The first region of activation 
is found -1528 to -1921 upstream of the transcription start site, while the second region is 
found at -2271 to -2618.  These two regions both confer an increase of approximately 2-
fold in activity and suggest important regulatory factors bind in these areas. 
Transfection of the same PRDM1 constructs into the CA46 lymphoma cell line 
revealed a similar pattern of activation through the proximal 521 promoter and the distal -
1528 to -1921 activator (figure 10B).  However, the region between -2271 and -2618 was 
not active in lymphoma cells.  While it is not possible to definitively compare absolute 
activity levels in transient transfections between different cell lines, the 2618 promoter 
construct shows consistently higher expression in the U266 myeloma cells, which 
correlates with higher expression of the endogenous gene expression in these cells. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.  Characterization of PRDM1 promoter activity in CA46 lymphoma cells 
and U266 myeloma cells. CA46 lymphoma cells and U266 myeloma cells were 
transiently transfected with PRDI-BF1 promoter deletion constructs fused to the 
luciferase reporter gene to map regions of activation.  A, U266 cells show elevated levels 
of promoter activity in the proximal promoter.  Regions of activation are located -1528 to 
-1921 and -2271 to -2618 relative to the transcription start site.  B, CA46 lymphoma cells 
show increased activity at the proximal promoter.  There is also one region of activation 
located -1528 to -1921 relative to the transcription start site.  Data shown are the mean of 
3 experiments for both figures. 
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Identification of putative factor binding sites in the PRDI-BF1 promoter 
To further elucidate what transcription factors are responsible for the activation of 
the promoter in these cells, we employed in vivo genomic footprinting to identify where 
factors are bound to the promoter in these putative regulatory regions.  Examination of 
the region proximal to the transcription start site demonstrated factor binding in both the 
lymphoma and myeloma cells (figure 11).  These sites are similarly occupied in both cell 
types.  A cluster of contacts closest to the transcription start site are centered over a 
sequence with homology to a Sp1 element.  Sp1 binding was confirmed by 
electrophoretic gel mobility shift assay and specific antibody reactivity (figure 12).  The 
P.A and P.B contact points do not have obvious homology with known elements.  
 To examine the more distal promoter regions by in vivo footprinting, 
approximately 600 bp were scanned between -1600 to -2200 and 400 bp between -2200 
and -2600.  We utilized ten in vivo footprinting primer sets to display both the upper and 
lower strands across these regions. The majority of contacts were in the region -1700 to -
2100.  Three cell line-specific interactions, which are denoted as P.C, P.F, and P.H 
(figure 13), were found in this region.  The other indicated protein-DNA interactions (i.e., 
P.D, P.E, P.F, P.I, and P.J) are found in both lymphoma and myeloma cells.  Site P.C is 
located at -2067 and is a myeloma-specific factor.  Sites P.F and P.H are located at -1974 
and -1742, respectively, and are lymphoma specific factors.  Site P.J is located at -1807, 
and has been previously characterized as the AP-1 element binding site by Vasanwala et 
al. (271).  Because the -2271 to -2618 region is a myeloma-specific region of activation, 
we thoroughly examined this region of the promoter, but found no unique contacts in this 
region (figure 14). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.  In vivo genomic footprinting of the PRDI-BF1 proximal promoter 
reveals numerous protein-DNA interactions in both lymphoma and myeloma cells.  
A, 8226 myeloma and CA46 lymphoma cells were analyzed for interactions at the first 
160 basepairs of the promoter region using the PRDLOW2 primer set.  The control lanes 
show the in vitro methylated guanine residues, while the DMS lanes show the in vivo 
methylated residues.  Protections (closed arrowheads) and enhancements (open 
arrowheads) are shown on the right side of each footprint panel and indicated in the 
sequence by black or gray, respectively, triangles.  Potential elements are labeled site P.A 
and P.B.  B,  8226 myeloma and Raji lymphoma cells were analyzed for interactions at 
the first 275 basepairs of the promoter region.  The Sp1 element was confirmed in vitro 
(see figure 12).  8226 and Raji fooprints used PRD UP primer 1 combined with PRDPI 
primers 2 and 3. 
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Figure 12.  Sp1 binds the PRDI-BF1 proximal promoter.  EMSA assays were done 
using an oligonucleotide containing the Sp1 consensus sequence and Raji lymphoma cell 
nuclear extract.  Competitor oligonucleotides were added to the binding reaction at 25- to 
50-fold molar excess.  0.2 µg of either Sp1 or ATF-1 antibody were used where 
indicated.  The Sp1 complex is supershifted by addition of Sp1 antibody (lane 3), while 
addition of non-specific ATF-1 antibody (lane 4) shows no change from the probe only 
(lane 1).   
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 Figure 13.  In vivo genomic footprinting of the PRDI-BF1 promoter region -1528 to -1921 bp distal to the transcription start 
site reveals numerous protein-DNA interactions in both lymphoma and myeloma cells.  A, U266 myeloma and CA46 lymphoma 
cells were analyzed for in vivo interactions in the region between -1897 to -2072 bp using PRD C primer set.  The control lanes show 
the in vitro methylated guanine residues, while the DMS lanes show the in vivo methylated residues.  Protections (closed arrowheads) 
and enhancements (open arrowheads) are shown on the right side of each footprint panel and indicated in the sequence by black or 
gray, respectively, triangles.  B, U266 myeloma and CA46 lymphoma cells were analyzed for in vivo interactions in the region 
between -1718 to -1895 bp using PRD H primer set.  Site P.H is a novel protection found only in the CA46 cells.  C, H929 myeloma 
and CA46 lymphoma cells were analyzed for in vivo interactions in the region between -1811 to -1966 bp using PRD D set.   There 
are no unique interactions in this specific region. 
 
48 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14.  In vivo genomic footprinting of the PRDI-BF1 promoter -2271 to -2491 
bp distal to the transcription start site reveals no protein-DNA interactions in both 
lymphoma and myeloma cells.  A, U266 myeloma and Raji lymphoma cells were 
analyzed for in vivo interactions in the region between -2273 to -2431 bp.  B, U266 and 
8226 myeloma and Raji lymphoma cells were analyzed for in vivo interactions in the 
region between -2381 and -2544 bp.  The control lanes show the in vitro methylated 
guanine residues, while the DMS lanes show the in vivo methylated residues.  There are 
no apparent protections in this region of the promoter in either myeloma or lymphoma 
cells.  This region was analyzed using the PRD 0.4K FWD  and PRD 0.4K REV primer 
sets, respectively.   
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Identification of a functional factor binding site on the PRDI-BF1 promoter 
 Sites P.C, P.F, and P.H, which were occupied in a cell type-specific manner, were 
mutated within the PRD 1921 and 2618 promoter constructs.  Transfection of the mutated 
constructs into either lymphoma or myeloma cells demonstrates sites P.C and P.F are not 
required for PRDM1 promoter activity (figure 15).  However, mutating the lymphoma-
specific factor P.H in both constructs decreases promoter activity by approximately 50% 
when transfected into CA46 lymphoma cells.  There is a slight effect on promoter activity 
in U266 myeloma cells, but the decrease in activity of the mutated constructs when 
compared to the wild-type constructs is much less dramatic (figure 16).  These data 
correlate with the occupation of site P.H in a lymphoma-specific manner in the footprints. 
 Gel shift assays were done to confirm factor-binding in a specific manner at site 
P.H.  Examination of both CA46 lymphoma and U266 myeloma cells demonstrate 
specific binding of factor P.H in the lymphoma cells.  Site P.H is homologous to an Ets 
factor binding site.  PU.1 is a B cell specific Ets family member (172), so we examined 
its ability to bind P.H in lymphoma and myeloma cells.  Addition of antibody against 
PU.1 competes out binding to P.H in CA46 lymphoma cells (figure 17A), but has no 
effect on P.H binding in U266 myeloma cells (figure 17B), which correlates with the lack 
of PU.1 expression in myeloma cells (172).  PU.1 is known to bind DNA in a complex 
with IRF family members on other promoters (58, 61), so we examined numerous IRF 
family members to determine if they also bound the PRDM1 promoter in CA46 
lymphoma cells at site P.H.  However, using IRF-4 and IRF-8 antibodies did not shift or 
cause a disappearance of the P.H binding site, indicating that these factors do not bind 
site P.H in CA46 lymphoma cells (figure 18).   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15.  Site-directed mutagenesis demonstrates sites P.C and P.F are not 
necessary for activity of the PRDI-BF1 promoter in either CA46 lymphoma cells or 
U266 myeloma cells. A, Mutating the P.C and P.F sites in the PRD 2618 promoter 
deletion construct had no effect on promoter activity in CA46 lymphoma cells.  B, In the 
U266 myeloma cells, there is also no change in mutant promoter activity when compared 
to wild type promoter activity.  Promoter activity was normalized to Renilla activity and 
pGL3 basic activity set to 1.  The mean of 3 independent experiments is shown with 
standard deviations.  
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Figure 16.  Site-directed mutagenesis demonstrates site P.H is necessary for activity 
of the PRDI-BF1 promoter in CA46 lymphoma cells, but not in U266 myeloma cells. 
A, Mutating the P.H site in both the PRD 1921 and PRD 2618 promoter deletion 
constructs decreases promoter activity in CA46 lymphoma cells by approximately 50%.  
B, In the U266 myeloma cells, there is minimal change in mutant promoter activity when 
compared to wild type promoter activity.  Promoter activity was normalized to Renilla 
activity and pGL3 basic activity set to 1.  The mean of 6 independent experiments is 
shown with standard deviations.  
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Figure 17.  Site P.H is a PU.1 factor binding site in CA46 lymphoma cells, but not 
U266 myeloma cells.  Gel shift assays were done using an oligonucleotide containing the 
P.H consensus sequence and CA46 or U266 nuclear extract.  A, Competitor 
oligonucleotides were added to the binding reaction at 150- to 300-fold molar excess.  1 
µg IRF-4 antibody and 0.5-4 µg PU.1 antibody was used.  The P.H complex is shifted by 
addition of PU.1 antibody, while addition of IRF-4 antibody does not affect the 
complexes.  B, Competitor oligonucleotides were added to the binding reaction at 20- to 
40-fold molar excess.  0.2 ug IRF-4 antibody, 0.5 ug PU.1 antibody (BD Pharmingen), 
0.2 ug PU.1 antibody (Santa Cruz), or 0.2 ug Sp1 antibody were used.  There is no factor 
binding to site P.H in U266 myeloma cells. 
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Figure 18.  Site P.H is not a IRF-4 or IRF-8 factor binding site in CA46 lymphoma 
cells.  Gel shift assays were done using an oligonucleotide containing the P.H consensus 
sequence and CA46 nuclear extract.  Competitor oligonucleotides (specific cold P.H, 
mutant P.H, and non-specific Sp1) were added to the binding reaction at 25- to 50-fold 
molar excess.  0.2 µg IRF-4 antibody and 0.5 µg IRF-8 antibody was used.  Addition of 
IRF-4 or IRF-8 antibody does not affect the P.H binding.   
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PU.1 is involved in anti-IgM-mediated transcriptional regulation of PRDI-BF1 
To determine if PU.1 is involved in the activation of the PRDM1 promoter by B 
cell receptor cross-linking, CA46 lymphoma cells were transfected with PU.1 siRNA and  
treated with anti-IgM.  Treatment of cells for 24 hours with anti-IgM demonstrated a 
decrease in anti-IgM-mediated induction of PRDI-BF1 mRNA levels (figure 19A).  
Additionally, treatment of cells for 1 hour with anti-IgM demonstrated a marked decrease 
in anti-IgM-mediated PRDI-BF1 nascent RNA induction (figure 19B).  PU.1 siRNA 
specifically targeted PU.1, but not PRDI-BF1, as demonstrated in  figure 19C.  These 
data indicate that PU.1 is one of the factors involved in anti-IgM induced transcription of 
PRDM1. 
 
The PI3K and MAPK signaling pathways are involved in anti-IgM-mediated 
induction of PRDI-BF1 in lymphoma cells 
 To investigate the role of signaling pathways involved in anti-IgM-mediated 
induction of PRDI-BF1 in CA46 lymphoma cells, preliminary experiments were done 
utilizing the MAPK inhibitor U0126 and the PI3K inhibitor Wortmannin.  Pretreatment 
of cells with these compounds inhibited anti-IgM-mediated induction of PRDI-BF1 
mRNA levels (figure 20), indicating these pathways are involved in the induction of 
PRDM1.  However, further investigation will need to be done to elucidate the role of 
these pathways in regulating PRDI-BF1.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19.  PU.1 is involved in anti-IgM-mediated transcriptional regulation of 
PRDI-BF1.  A, CA46 lymphoma cells transfected with either MARK (neg) or PU.1 
siRNA were treated with anti-IgM for 24 hours and PRDI-BF1 mRNA levels were 
detected.  B, Cells were also treated for 1 hour with anti-IgM and PRDI-BF1 nascent 
RNA levels were measured.  C, PU.1 mRNA levels are decreased using PU.1 siRNA 48 
hours after transfection.  Additionally, PU.1 mRNA levels are unaffected by anti-IgM 
treatment.  The data are representative of 2 experiments done in duplicate. 
56 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 20.  The PI3K and MAPK signaling pathways are involved in the anti-IgM-
mediated induction of PRDI-BF1.  CA46 lymphoma cells were pretreated with the 
PI3K inhibitor Wortmannin or the MAPK inhibitor U0126 for 2 hours, followed by 
treatment with 10 µg/ml anti-IgM for 4 hours.  Control cells had a 5-fold induction in 
PRDI-BF1 mRNA levels, while cells undergoing pretreatment with either inhibitor 
lacked an induction of PRDI-BF1.    
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Discussion 
 The transcription factor PRDI-BF1/Blimp-1 is required for the differentiation of a 
mature B cell to a plasma cell (237).  It does this by directly repressing downstream 
targets, which in turn has a widespread effect on further downstream targets (236).  These 
downstream effector cascades have been well studied, however very little is known as to 
how PRDI-BF1/Blimp-1 expression is regulated.  Bcl-6 is known to repress PRDI-BF1 
by acting through AP-1 elements (271) and IRF-8 is known to activate PRDI-BF1 in 
murine myeloid progenitor cells (252).   
 This study demonstrates a direct link between B cell receptor cross-linking by 
anti-IgM and transcriptional activation of PRDI-BF1/Blimp-1.  Treatment of CA46 
lymphoma cells with anti-IgM significantly induced PRDM1 mRNA levels, caused 
apoptosis, and increased activity of the PRDM1 promoter.  Because there was no change 
in mRNA stability with anti-IgM treatment, while actively transcribing nascent RNA 
levels were rapidly induced, this indicated regulation occurs primarily at the level of 
transcription.  Nascent RNA levels are very low in CA46 lymphoma cells, but in 
myeloma cells they are significantly higher.  While nascent RNA levels can be rapidly 
induced upon BCR cross-linking to levels significantly higher than that of control cells, 
luciferase activity is only nominally induced by BCR cross-linking.  This could be due to 
the IgM response element on the PRDM1 promoter being located more than 2618 bp 
distal to the transcription start site, which is the PRDM1 promoter construct tested.  
Rapid induction of nascent RNA levels by B cell receptor cross-linking and the evidence 
of a promoter with many protein-DNA interactions detected by in vivo genomic 
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footprinting indicate the PRDM1 promoter is occupied and primed for transcription in 
lymphoma cells, even though PRDI-BF1 gene expression is not detectable.   
This is comparable to the situation in T cells, which also do not express PRDM1.  
However, it has recently been shown that activating CD4+ T cells in vitro will elevate 
PRDM1 levels equivalent to that of splenic B cells treated with LPS (111).  Our findings 
in lymphoma cells are also important in light of recent evidence which demonstrates the 
presence of PRDI-BF1 gene expression in DLBCL  (32, 195, 251).  Mutations of PRDM1 
were found in 23% of DLBCL patient samples examined (251).  Another group further 
characterized their DLBCL patient population and determined only the activated B cell-
like DLBCL samples were positive (24%) for mutated PRDM1 expression (195).  
Alterations in PRDM1 included frameshift mutations, point mutations, chromosomal 
inversions and, most importantly, all led to PRDM1 gene inactivation (195, 251).  
Mutations in DLBCL suggest a potential role for PRDI-BF1 as a tumor suppressor, 
consistent with its differentiation and apoptosis promoting effects. 
Our work is the first to directly link the expression of PRDI-BF1/Blimp-1 to anti-
IgM mediated B cell receptor activation.  It has long been known that anti-IgM induces 
apoptosis in lymphoma cells (12, 30, 87, 112, 299) and has been correlated with 
decreased levels of c-myc expression (112), a direct target of PRDI-BF1 (140).  The 
BCL1 murine B cell model was used to demonstrate phenotypic differences resulting 
from the introduction of Blimp-1 into partially activated mature 5B1b and activated 3B3 
cells, a cell line derived from the 5B1b line.  Blimp-1 is able to induce apoptosis in the 
mature 5B1b cell line (164), as well as numerous other B cell lines in the early stages of 
development (119, 164).  However, in the activated 3B3 cells, ectopic expression of 
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Blimp-1 induces differentiation (164).  Our study directly correlating apoptosis with 
increased PRDM1 mRNA expression is important because it may be possible to induce 
apoptosis in PRDM1-negative lymphoma cells by inducing PRDI-BF1 expression levels.  
Furthermore, PRDI-BF1 has been shown to be an important target in immunotherapy of 
myeloma by induction of PRDI-BF1-specific CTLs (150).   
 Regions of PRDM1 promoter activation are localized to two distal regions in 
U266 myeloma cells and one distal region in CA46 lymphoma cells.  In vivo genomic 
footprinting of the regions of activation in both lymphoma and myeloma cells yielded 
multiple protein-DNA interactions.  One of these was site P.J, which is the AP-1 factor 
binding site shown to be important for Bcl-6-mediated repression of the PRDI-BF1 
promoter by Vasanwala et al (271).  Our in vivo footprinting data show site P.J is 
occupied in both CA46 lymphoma and U266 myeloma cells. Another study in the murine 
system suggested c-Fos acting through distinct elements is a key transcription factor for 
Blimp-1 expression in activated B cells, regardless of Bcl-6/AP-1 element interactions 
(185).  Our findings of factor binding at site P.J in both lymphoma and myeloma cells 
support a BCL-6 independent role for c-fos/AP1 at site P.J, as myeloma cells do not 
express Bcl-6 (272).  The distal region of activation specific for only myeloma cells 
demonstrated no protein-DNA interactions, indicating factors may be bound to this 
region but are undetectable using DMS in vivo footprinting which recognizes methylated 
guanine residues.   
 Several cell-type specific interactions, namely P.C, P.F, and P.H, were observed 
by in vivo footprinting.  Basal and anti-IgM stimulated PRDM1 promoter activity was 
significantly inhibited by mutating the P.H site in lymphoma cells.  This indicates P.H, 
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which shares homology with Ets family member binding sites, is an important functional 
site for PRDM1 promoter regulation.  PU.1 is an Ets family member found only in B cells 
(172) and is bound to P.H, as demonstrated by electrophoretic mobility gel shift assay.  
PU.1 antibody supershifted the P.H complex.  Ets and IRF family members have been 
reported to complex with one another and bind promoters (58, 61).  In addition, the 
transcription factor IRF-8/ICSBP has been shown to directly induce Blimp-1 expression 
in myeloid cells (252). However, we did not detect specific binding of IRFs at the P.H 
site in CA46 lymphoma cells. This suggests that either other undetected IRF elements 
exist or the activity of IRF-8 on PRDM1 is specific for myeloid cells.  This study further 
demonstrated a role for PU.1 in anti-IgM-mediated induction of PRDM1 in lymphoma 
cells, as introduction of PU.1-specific siRNA in lymphoma cells diminished the anti-
IgM-mediated induction of PRDI-BF1 mRNA expression.  However, PRDM1 expression 
was only reduced approximately 50%, indicating PU.1 is not the sole factor responsible 
for anti-IgM-mediated induction of gene expression.  Preliminary data using inhibitors to 
the MAPK and PI3K signaling pathways indicate these pathways are involved in 
inducing PRDI-BF1 in CA46 lymphoma cells.  However, further experiments are 
required to elucidate additional factors responsible for inducing PRDI-BF1 in lymphoma 
cells using anti-IgM. 
 In conclusion, we have demonstrated PRDM1 regulation occurs primarily at the 
transcriptional level in lymphoma and myeloma cells.  We have also demonstrated the 
involvement of PU.1 in basal and anti-IgM induced activation of the PRDM1 promoter in 
lymphoma cells.  Importantly, we report that the promoter is poised and ready for 
activation in lymphoma cells, suggesting that inducing PRDI-BF1 expression in 
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lymphoma cells lacking PRDM1 gene mutations is a viable therapeutic approach to 
inducing apoptosis in these cells.
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Materials and Methods 
 
Cell lines and drugs 
The RPMI-8226, U266, and NCI-H929 multiple myeloma and CA46, Raji, and 
BJAB Burkitt’s lymphoma cell lines were maintained in RPMI medium (Invitrogen) 
supplemented with 10% fetal bovine serum (FBS) (HyClone), and 1% 
penicillin/streptomycin (P/S) (Invitrogen).  The NCI-H929 cell line was also 
supplemented with 0.05 M β-mercaptoethanol (Sigma, St. Louis, MO).  Bone marrow 
cells derived from myeloma patients were obtained from the H. Lee Moffitt Cancer 
Center Tissue Bank under Institutional Review Board approval.  Normal adult bone 
marrow samples were obtained from the H. Lee Moffitt Cancer Center Tissue Bank and 
Stratagene.  Goat anti-human IgM antibody (Southern Biotechnology) was used at 10 
µg/ml.  Actinomycin D (Sigma) was used at 10 µg/ml to determine mRNA stability.  
Trypan blue exclusion was used to determine total live cell counts. 
 
Apoptosis assay 
 Cells were treated with anti-IgM continuously for 24 hours, followed by Annexin 
V-PE and 7-AAD staining per manufacturer’s protocol (BD Pharmingen).  Flow 
cytometry acquisition was done on a FACSCalibur and analyzed with CellQuest software 
(Becton Dickinson, Carpinteria, CA). 
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Real-time PCR 
 RNA was isolated from cells using TriZol reagent (Invitrogen) and the 
manufacturer’s protocol.  One µg RNA was DNase-treated using RQ1 DNase (Promega), 
followed by first-strand cDNA synthesis using the iScript cDNA synthesis kit (Bio-Rad).  
1/20th of the final cDNA reaction volume was used in each PCR reaction.  Primers 
sequences are as follows:  PRDI-BF1 FWD, 5’- TACATACCAAAGGGCACACG -3’, 
PRDI-BF1 REV, 5’- TGAAGCTCCCCTCTGGAATA -3’, PU.1 FWD, 5’- 
AGCAGATGCACGTCCTCGATA -3’, PU.1 REV, 5’- 
AGACCTGGTGGCCAAGACTG -3’, GAPDH FWD, 5’- 
GAAGGTGAAGGTCGGAGT -3’, and GAPDH REV, 5’- 
GAAGATGGTGATGGGATTTC -3’.  Primer sets were run using an annealing 
temperature of 60oC.  Real-time PCR reactions were performed in a volume of 25 µl, 
which included 200 nM of each forward and reverse primer and iQ  SYBR Green 
Supermix (Bio-Rad).  Reactions were run in duplicate using an iCycler and iQ software 
Version 1.0 (Bio-Rad).  Average threshold cycles (Ct) for the genes of interest were 
normalized to the average GAPDH Ct values for each cDNA sample and relative levels 
of the genes of interest were calculated by the ∆∆Ct method (145):  for example, 2-(PRDI-
BF1-GAPDH) for PRDI-BF1 gene expression. 
 
Isolation of nascent RNA 
 Nascent RNA was isolated as previously described (121, 283).  Briefly, nuclei 
from lymphoma and myeloma cells was isolated in a RNase-free buffer comprised of 140 
mM NaCl, 1.5 mM MgCl2, 0.5% NP-40, 1000 U/ml RNase OUT (Invitrogen), 1 mM 
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DTT, and 50 mM Tris, pH 8.  Extracted nuclei were washed in this buffer three times to 
remove cytoplasmic RNA, followed by lysis in a RNase-free buffer containing 300 mM 
NaCl, 1 M urea, 1% NP-40, 7.5 mM MgCl2, 0.5 mM EDTA, 1 mM DTT, and 20 mM 
HEPES, pH 7.6 to isolate histone-bound chromatin.  RNA isolation was done as 
described above.  Nascent RNA levels were measured by real-time PCR. 
 
DNA constructs 
 PRD 2618, originally referred to as PRDM1α, was cloned as previously described 
(80).  Using PRD 2618 as a cloning template, PRD 521 was sub-cloned using a 
NheI/SmaI digest to remove the 521 bp fragment, blunt-ended, and cloned into pGL3 
basic.  PRD 1648 was cloned by digesting PRD 2618 with BglII to yield a 1648 bp 
fragment, which was then ligated into pGL3 basic.  PRD 1921 was cloned by digesting 
PRD 2618 with Kpn/PacI to remove 703 bp.  PRD 2391 was derived from PRD 2618 by 
digestion with HindIII to remove 2391 bp and cloned into pGL3 basic.  PRD 983 and 
PRD 2041 were PCR-cloned.     
 Site-directed mutagenesis was done by PCR cloning the mutated sequence into 
the PRD 1921 or PRD 2618 constructs.  Briefly, mutations were introduced into either 
construct using a common PRD 2618 forward or reverse primer, paired with either a 
reverse or forward primer, respectively, containing the site mutation.  Primer sets used 
are as follows, with the mutated bases indicated in lower case letters:  PRD 2618 FWD, 
5’- TTCCTATTATGGAGCAAGCTTCC -3’, PRD 2618 REV, 5’- 
CATTTCTCCTTCGACCTGCA -3’, P.C mut FWD, 5’- 
CCTTAAAGTTCTAtttaaagCCTTGTCCAGCTC -3’, P.C mut REV, 5’- 
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GAGCTGGACAAGGctttaaaTAGAACTTTAAGG -3’, P.F/G mut FWD, 5’- 
GTTTGCGTCCTaaagctagcCAAGCCCATTTCAC -3’, P.F/G mut REV, 5’- 
GTGAAATGGGCTTGgctagctttAGGACGCAAAC -3’, H3 mut FWD, 5’ - 
ATTCTAAAAGGaAcGTtAAATACTCTTTAAC - 3’, and H3 mut REV, 5’ - 
GTTAAAGAGTATTTaACgTtCCTTTTAGAAT - 3’.  PCR products were gel-purified 
and paired with their respective mutation partner and amplified using PRD 2618 common 
primers.   PRD 1921 mut P.H was derived from the PRD 2618 mut P.H construct by 
digesting with KpnI/PacI, removing a 703 bp fragment, and re-ligating the vector.  All 
mutations were confirmed by sequencing. 
 
Luciferase assays 
 Cells were transfected by electroporation using the Gene Pulser II (Bio-Rad, 
Hercules, CA).  Cells (1 x 107) were pulsed with 250 V at a capacitance of 1070 µF.  
Transfections were done with 10 µg of luciferase reporter construct and 50 ng of the 
internal control plasmid pRL-TK.  Cells were placed in complete medium for 42-48 
hours and harvested for luciferase activity per the Dual-Luciferase Reporter Assay 
System protocol (Promega).  Luciferase readings were done using the 20/20n 
luminometer (Turner Biosystems).  Firefly luciferase activity was normalized to Renilla 
luciferase activity in all experiments. 
 
Dimethyl sulfate in vivo footprinting 
 In vivo methylation of cells with dimethylsulfate (DMS) and subsequent isolation 
of DNA was done as previously described (75, 199).  Cells were in vivo-treated with 1 
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µl/ml DMS and methylation of guanine residues was ensured by occasional swirling for 5 
minutes at 37oC.  The reaction was stopped by adding ice-cold PBS plus 60 mM Tris, pH 
7.5, and washing twice.  Cells were lysed in lysis buffer (100 mM EDTA, 60 mM Tris, 
pH 7.5, 0.1% SDS, 500 µg/ml Proteinase K (Roche)) for 4 hours at room temperature.  
Samples were stored at 4oC or genomic DNA was extracted immediately.   
 To extract genomic DNA, samples were brought to room temperature to bring the 
SDS back into solution.  DNA was extracted using phenol (Roche)/chloroform:isoamyl 
alcohol (24:1) and washed twice with chloroform:isoamyl alcohol (24:1).  DNA was 
precipitated by adding 1/10 volume 3 M NaAc (pH 7) and 2.5 volumes 95% ethanol, 
followed by spooling with a hooked Pasteur pipet to remove the DNA.  DNA was 
resuspended in 3-5 ml Tris:EDTA (10 mM:0.1 mM).  Genomic DNA was digested with 
either 100 units HindIII or PstI (NEB) and extracted as above. 
 Control samples were treated with 1 µl DMS for 20 seconds.  The reaction was 
stopped by adding DMS stop buffer (1.5 M NaAc, pH 7, 1 M β-mercaptoethanol, 100 
µg/ml tRNA (Ambion)).  DNA was precipitated by adding -20oC 95% ethanol and snap-
freezing in a dry-ice/ethanol bath for 10 minutes, washed twice with cold 75% ethanol, 
and dried by Speed-Vac.  DNA was cleaved at guanine residues by adding 200 µl 
piperdine (diluted 1:10 in ice-cold H2O) and incubating at 90oC for 30 minutes.  DNA 
was precipitated and lyophilized to dryness in a Speed-Vac.  DNA was washed twice 
with H2O, lyophilized to dryness, and resuspended in 50 µl H2O.   
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Ligation-mediated PCR (LM-PCR) 
 Primers for the ligation-mediated PCR, LM-PCR, are shown in Table 1 with Tms 
used in each reaction.  Full-length primers were purified using denaturing polyacrylamide 
gel electrophoresis.  Briefly, primers were incubated with an equal volume formamide at 
55oC for 5 minutes.  Products were separated using a pre-run 16% polyacrylamide gel (7 
M urea, 20:1 acrylamide/bisacrylamide, 1x TBE) run at 1500 V for 1 hour.  UV 
shadowing was used to distinguish between full-length primers and prematurely 
terminated products.  Primers were extracted from the gel using an EluTrap (Schleicher 
and Schuell) and passed over a Sep-Pack column (Waters) using a 10 ml syringe and 
slow flow rate.  The column was equilibrated by adding 10 ml 100% acetonitrile and 20 
ml water.  The extracted primer was added in 1.5 ml volume water and eluted using 10 
ml fresh 25 mM ammonium bicarbonate (ABi), 10 ml ABi/5% acetonitrile, 20 ml 
water/5% acetonitrile, and 4 ml water/30% acetonitrile.  Primers were dried in a Speed-
Vac and resuspended in water. 
 LM-PCR was performed as previously reported (169, 282).  Approximately 7.5 
µg DMS-treated genomic DNA was annealed to 0.3 pmol primer 1 by first denaturing for 
4 minutes at 95oC and then annealing for 30 minutes at the Tm reported in Table 2 in a 15 
µl solution containing 1x Mg-free Sequenase buffer (40 mM Tris, pH 7.7 and 50 mM 
NaCl).  Primer extension was performed by adding 7.5 µl Mg/DTT/dNTP solution ((20 
mM MgCl2, 20 mM DTT, 0.2 mM each dNTP (USB)) and 1.5 µl diluted Sequenase 2.0 
(USB) (diluted 1:4 in ice-cold TE) and incubating for 10 minutes at 47oC, 5 minutes at 
60oC, and holding at 22oC.  The Sequenase extension reaction was stopped by adding 6 
µl 310 mM Tris, pH 7.7 and incubating at 67oC for 10 minutes.  Ligation of the 
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hybridized linker (hybridized long linker and short linker primers) to the above reaction 
product was done by adding 20 µl dilution solution (17.5 mM MgCl2, 42.3 mM DTT, 125 
µg/ml BSA) and 25 µl ligation mix (10 mM MgCl2, 20 mM DTT, 50 µg/ml BSA, 50 mM 
Tris, pH 7.7, 3 mM rATP (Promega), 100 pmol hybridized linker per reaction, 400 U T4 
DNA ligase (NEB)) and ligating overnight at 16oC.  The ligation products were 
precipitated with 1/10 volume 3 M NaAc, pH 7, 10 µg tRNA (Ambion), and 95% 
ethanol, air-dried, resuspended in 70 µl water, and 30 µl PCR mix (40 mM NaCl, 10 mM 
Tris, pH 8.9, 5 mM MgCl2, 0.01% (w/v) gelatin, 20 nmol dNTPs, 10 pmol primer 2, 10 
pmol long linker primer, 5 U Ampli-Taq (Applied Biosystems)) was added.  The PCR 
reaction was heat denatured at 97oC for 3.5 minutes, primer 2 annealed at the appropriate 
Tm (see Table 1), and extended at 76oC for 3 minutes.  PCR products were amplified 
with 16 cycles of heat denaturation for 1 minute at 97oC, annealing of primer 2 at the 
appropriate Tm, and extension at 76oC for 3 minutes, 5 seconds, with an additional 
extension of 5 seconds each cycle.  One final cycle of PCR was performed by heat 
denaturation for 1 minute at 97oC, primer 2 annealing for 2 minutes at appropriate Tm, 
and final extension for 10 minutes at 76oC.  PCR products were purified by 
phenol/chloroform extraction and ethanol precipitation and resuspended in 15 µl loading 
dye (80% formamide, 0.5x TBE, bromophenol blue, xylene cyanol).  PCR products (10 
µl) were size-fractionated using a pre-run 6% polyacrylamide wedge sequencing gel 
made with 7.75 M urea, 20:1 acrylamide/bisacrylamide (Bio-Rad), and 1x TBE.  The gel 
was dried and products were visualized by autoradiography. 
 Primer 3 was radioactively labeled in a kinase reaction mix containing 20 pmol 
primer, kinase buffer (NEB), 150 µCi γ-32P-ATP (Amersham), and 10 U polynucleotide 
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kinase (NEB).  Primer labeling occurred by incubating for 45 minutes at 37oC, followed 
by heat inactivation of the enzyme for 10 minutes at 68oC.  Unincorporated ATP was 
removed by using the Qiagen nucleotide removal kit and eluting labeled primer with 200 
µl H2O (pH 7.7).  The PCR product was radioactively labeled by annealing 20 pmol 
primer 3 in a reaction mix containing 40 mM NaCl, 10 mM Tris, pH 8.9, 5 mM MgCl2, 
0.01% (w/v) gelatin, 20 pmol dNTPs, and 5 U Ampli-Taq and annealing by cycling twice 
through 3.5 minutes of heat denaturation at 97oC, annealing at appropriate primer 3 Tm 
for 2 minutes, and extending at 76oC for 10 minutes. 
 
Nuclear extract preparation and electrophoretic mobility shift assays 
 Nuclear extracts were prepared according to Dignam et al. (53).  To summarize, a 
minimum of 3 x 108 cells were pelleted and the pellet cell volume (PCV) was estimated.  
Cells were resuspended in 5x PCV buffer A (10 mM Hepes, pH 7.9, 1.5 mM MgCl2, 10 
mM KCl, 0.5 mM DTT, and 0.5 mM PMSF) and swelled in this hypotonic buffer for 10 
minutes on ice.  Cells were resuspended in 2x original PCV buffer A and dounced with B 
pestle of the Dounce homogenizer until 95% of the cells were lysed.  The nuclei were 
isolated by a quick centrifugation at 30000 x g in a Beckman JA25.50 rotor.  The nuclear 
pellet was resuspended in 1 ml buffer C (modified) (20 mM Hepes, pH 7.9, 20% 
glycerol, 1.5 mM MgCl2, 0.2 mM EDTA, pH 8.0, 0.42 M KCl, 0.5 mM DTT, and 0.5 
mM PMSF)/1 x 109 cells.  Nuclei were extracted by agitating on a nutator for 20 minutes 
at 4oC, centrifuging for 30 minutes at 25000 x g in a 4oC Beckman JA25.50 rotor, and 
resuspending in dialysis buffer D (20 mM Hepes, pH 7.9, 20% v/v glycerol, 0.2 mM 
EDTA, pH 8.0, 0.5 mM DTT, and 0.5 mM PMSF). 
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 The Sp1 oligonucleotide sequence is 5’- 
GATCTGGCCACGCCCCCACTTCGCGC -3’.  The Sp1 mutant oligonucleotide 
sequence is 5’- GATCTGGCCACaaaaaCACTTCGCGC -3’.  The P.H oligonucleotide 
sequence is 5’- 
GATCCAGAGTTTGATTCTAAAAGGGAAGTGAAATACTCTTTAAC -3’.  The 
mutant P.H oligonucleotide contains the same mutation as in construct PRD 2618 mut 
H3.  The AP2α  oligonucleotide sequence is 5’- GATCAAGCCCTGGGCTCGGCCAG -
3’.  Gel shift probes were end-labeled using T4 polynucleotide kinase (NEB).  Five 
picomoles of radioactive probe were end-labeled with γ-32P-ATP and purified using mini 
Quick Spin DNA columns (Roche).  50 picomoles of cold competitor probe was 
synthesized using the same conditions as above.   
For each EMSA reaction, 4 µl of nuclear extract were combined with 0.5 mM 
DTT, 1 µg poly (dI:dC), and either antibody (0.2-4 µg) or 20-300-fold molar excess cold 
competitor oligonucleotides.  Antibody incubations occurred on ice for 1-2 hours, 
followed by labeling with 100000 counts of probe for 0.5 hours.  Gels were run cold for 
1.5 hours and DNA binding was observed by autoradiography.  PU.1 antibodies were 
obtained from BD Pharmingen and Santa Cruz, while IRF-1, IRF-2, IRF-4, ATF-1, and 
Sp1 antibodies were from Santa Cruz. 
 
Transfections with siRNA 
 CA46 lymphoma cells were transfected with 3 Hg MARK or PU.1 siRNA 
(Dharmacon) by electroporating 1 x 107 cells in 0.3 ml serum-free RPMI medium.  Live 
cells were isolated using a Ficoll gradient and washed in complete medium.  Cells were 
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treated for either 1 hour or 24 hours with 10 Hg/ml anti-IgM.  Following 1 hour 
incubation, cells were harvested for nascent RNA as previously described.  Following 24 
hour incubation, cells were harvested for mRNA, as previously described.   
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Table 1.  Primers used for LM-PCR.  Primers used to detect promoter region of 
interest, sequence of primers, and Tm for each LM-PCR reaction are listed. 
Primer name Sequence Tm 
Short linker 5’- GAATTCAGATC -3’ 64 
Long linker 5’- GCGGTGACCCGGGAGATCTGAATTC -3’ 64 
PRDI primer 2 5’- GGAGCTGCCTCAAACCGATTAACCCAC -3’ 66 
PRDI primer 3 5’- GCTGCCTCAAACCGATTAACCCACCACAGA -3’ 68 
PRDLOW primer 1 5’- TAAGCAGGGAGGGGAAGC -3’ 62 
PRDLOW primer 2 5’- AGTGTTGCGGAGAGGCAAGAGCAG -3’ 65 
PRDLOW primer 3 5’- TTGCGGAGAGGCAAGAGCAGCGACCG -3’ 69 
PRDUP primer 1 5’ ACCCAGTCCACATTCTC -3’ 57 
PRDUP primer 2 5’- AGGCTGAGCCGCACAGACGCGCAC -3’ 70 
PRDUP primer 3 5’- ACAGACGCGCACCTCGGCGGTCCCTC -3’ 72 
PRDLOW2 primer 1 5’- GTACCTGGGGATTTGAGC -3’ 60 
PRDLOW2 primer 2 5’- AGGAACGTGCGCCCCCTAATTCTGCCGC -3’ 70 
PRDLOW2 primer 3 5’- CGTGCGCCCCCTAATTCTGCCGCGCCAG -3’ 73 
PRDUP2 primer 1 5’- GCTTTCCCCCAGATTGC -3’ 60 
PRDUP2 primer 2 5’- AGCACAGCCGCCGAGAGCTTCCTC -3’ 68 
PRDUP2 primer 3 5’- GCCGCCGAGAGCTTCCTCTCTTCGCATG -3’ 70 
PRD 0.4K FWD primer 1 5’- CTGAGGTTCTTTTCGGTG -3’ 58 
PRD 0.4K FWD primer 2 5’- CCAGACAGTGGCAGCCTCTGATAGC -3’ 65 
PRD 0.4K FWD primer 3 5’- GTGGCAGCCTCTGATAGCTCTCTCTGCAC -3’ 68 
PRD 0.4K REV primer 1 5’- ATTTAGGTATTGTCCAGCAC -3’ 56 
PRD 0.4K REV primer 2 5’- CCATTAAGGGGGAATAAAAGGGACTGACC -3’ 62 
PRD 0.4K REV primer 3 5’- CCATTAAGGGGGAATAAAAGGGACTGACCTCTG -3’ 66 
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Table 1 (continued from previous page)
PRD A1 5’- CCACGGGAATAGATGAG -3’ 57 
PRD A2 5’- CTGAGAACAGAACTATTTGGCTCATTCAT -3’ 64 
PRD A3 5’- CTATTTGGCTCATTCATGATTTGCTGCCATTG -3’ 68 
PRD B1 5’- AGCCTCTGATAGCTCTC -3’ 57 
PRD B2 5’- CTCTGGGAGGACCGAGTGAAGTTC -3’ 68 
PRD B3 5’- GGAGGACCGAGTGAAGTTCAGAGGTCAG -3’ 72 
PRD C1 5’- CAAGAAGCAAACATGTGAAG -3’ 57 
PRD C2 5’- GCAAACATGTGAAGGACTTTACATTCCAAC -3’ 68 
PRD C3 5’- GAAGGACTTTACATTCCAACACTCTGTGTCTG -3’ 72 
PRD D1 5’- GCTGGGACACCTGGAAC -3’ 57 
PRD D2 5’- CACTGGTATTTGAAGTTTGCGTCCTC -3’ 67 
PRD D3 5’- ATTTGAAGTTTGCGTCCTCCCTAGACTCAAGC -3’ 71 
PRD E1 5’- GCCTATTCCCTTACTCTATC -3’ 57 
PRD E2 5’- GTTGACTCACCAGCAGTTGCATGATG -3’ 64 
PRD E3 5’- CAGCAGTTGCATGATGGTGTATGTGGC -3’ 68 
PRD F1 5’- TTCTGTCCATTGTGGTGC -3’ 57 
PRD F2 5’- GACTCAGCATCAGTTAATAAACCCTC -3’ 67 
PRD F3 5’- GCATCAGTTAATAAACCCTCTTGAGCAG -3’ 71 
PRD G1 5’- GATTAGCACACACTCGC -3’ 57 
PRD G2 5’- CCACCTGTGATTGCATGTTATGCCAGAG -3’ 67 
PRD G3 5’- TGCATGTTATGCCAGAGGGGACGCTAGCAC -3’ 71 
PRD H1 5’- GAGTCAGCACCACAATG -3’ 57 
PRD H2 5’- CAATGTAGTCATACTGAAGGCTGGC -3’ 67 
PRD H3 5’- TCATACTGAAGGCTGGCCTGCTGTTC -3’ 71 
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Chapter Three 
 
Modulation of PRDM1 gene expression in lymphoma cells 
 
Introduction 
 Lymphomas encompass a group of cancers localized to the lymphoid system.  
The most frequent type of lymphomas are the B cell lymphomas (BCL) (219), a group to 
which both mantle cell lymphoma and Burkitt’s lymphoma belong.  Mantle cell 
lymphoma (MCL) is an aggressive form of non-Hodgkin’s lymphoma (NHL), accounting 
for approximately 5-8% of NHL cases.  Even though there are a variety of treatment 
regimens available to patients, it remains an incurable disease (279).  MCL is a distinct 
biologic subtype of NHL, demonstrated by high levels of cyclin D1 expression, which is 
caused by the t(11;14) (q13;q32) chromosomal translocation.  However, experiments 
using transgenic mice have demonstrated that this alone is not sufficient to cause MCL 
(151).  Another form of NHL is Burkitt’s lymphoma (BL), which has a very aggressive 
pathology and presents clinically as three different subtypes.  The endemic form of BL 
occurs at a 50-fold higher rate in equatorial Africa than in the United States.  The 
immunodeficiency subtype is found in patients with human immunodeficiency virus 
(HIV), while sporadic BL accounts for 1-2% of all adult lymphomas in the United States 
and Western Europe (19).  BL is characterized by overexpression of c-myc (136), often 
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caused by a t(8;14) translocation (73, 90, 177) or genetic alterations in the c-myc gene 
(92). 
 While Burkitt’s lymphoma adolescent patients have cure rates of 70%, older 
patients typically have a poorer response rate and many are unable to finish their 
treatment regimens due to cytotoxic side effects (63).  In the case of mantle cell 
lymphoma (MCL), many patients become refractory to treatment and their prognosis is 
poor (132).  Much excitement has been generated by newer chemotherapeutic drugs, such 
as the proteasome inhibitor Bortezomib, which has been fast-tracked for approval in 
MCL by the FDA based on phase 2 trial data (182).  In pre-clinical studies, Bortezomib 
was shown to induce apoptosis in both mantle cell lines and patient samples (196).  
Histone deactylase (HDAC) inhibitors are also effective drugs in lymphoma.  The new 
HDAC inhibitor LBH589 has potent antitumor activity in myeloma cells (155), while 
sodium butyrate and SAHA have been shown to induce apoptosis in mantle cell 
lymphoma cells (91).  HDAC inhibitors were shown to induce Blimp-1 gene expression 
in L10A murine lymphoma cells and induce differentiation, as shown by increased 
expression of the plasma cell surface marker Syndecan-1 (129).  However, targets of 
Bortezomib and HDAC inhibitors have not been fully elucidated to date.   
 Modulating PRDM1 expression in lymphoma cells may have therapeutic 
potential, as the promoter of lymphoma cells is poised for activation, as demonstrated by 
experiments using the B cell cross-linker anti-IgM (see Chapter Two).  The PRDM1 gene 
has recently been shown to be expressed in one form of lymphoma, namely DLBCL.  
However, inactivating mutations of PRDM1 were described in DLBCL, implicating this 
gene as a potential tumor suppressor in lymphoma (69, 195, 251).  In this study, the 
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activity of the proteasome inhibitor Bortezomib and the HDAC inhibitors Trichostatin A 
and LBH589 were assessed in CA46 Burkitt’s lymphoma and Mino mantle cell 
lymphoma cell lines.  These chemotherapeutic agents induce PRDM1 gene expression in 
both cell lines and patient samples, indicating these could drugs could have therapeutic 
potential in these aggressive forms of leukemia.   
 
Results 
Treatment with HDAC inhibitors or Bortezomib induce PRDM1 levels in 
lymphoma cell lines and mantle cell patient samples 
 Most B cells lack detectable levels of PRDM1 until they commit to differentiate  
(5, 24, 32, 69).  As shown in figure 7, lymphoma cell lines lack detectable levels of 
PRDM1.  These data correlate with low levels of nascent RNA purified from nuclei of 
these cells.  Levels of nascent RNA are an indicator of endogenous transcriptional 
activity in a cell (283).  When compared to U266 myeloma cells which express abundant 
levels of PRDI-BF1 nascent RNA, both CA46 and Mino cells have significantly lower 
levels of nascent RNA production (figure 21). 
  
 
 
 
 
 
 
 
 
 
Figure 21. Levels of nascent RNA in myeloma cells are elevated when compared to 
lymphoma cells. Relative levels of nascent RNA were determined by real-time RT-PCR 
for both CA46 and Mino lymphoma and U266 myeloma cells.  Levels in U266 myeloma 
cells are significantly higher than that of CA46 and Mino lymphoma cells (p<0.005, 
Student’s t-test).  
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  HDAC inhibitors have been shown to induce Blimp-1 mRNA expression in 
murine lymphoma cells (129) as well as inducing apoptosis (91, 218).  Trichostatin A 
treatment of CA46 cells induced PRDM1 expression in CA46 BL cells (figure 22).  
Because it has been recently established PRDM1 expression is regulated primarily at the 
level of transcription (see Chapter Two), cells were treated with Trichostatin A and 
analyzed for protein-DNA interactions at the proximal promoter by in vivo DMS 
footprinting.  However, analysis of one region of the promoter revealed no protein-DNA 
interactions (figure 23).  The clinically relevant HDAC inhibitor, LBH589, is able to 
induce PRDM1 expression in the Mino mantle cell lymphoma line, with a concomitant 
induction of apoptosis (figure 24).  However, when a patient sample was treated with the 
HDAC inhibitor SAHA, PRDM1 expression decreased at both 6 and 20 hours of 
treatment (figure 25).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22.  Treatment with the HDAC inhibitor Trichostatin A induces PRDI-BF1 
mRNA levels in CA46 lymphoma cells.  Treatment of CA46 lymphoma cells for 24 
hours with 100 ng/ml Trichostatin A significantly induces PRDI-BF1 mRNA levels.  The 
mean of 7 experiments is shown (p<0.0005, Student’s t-test).   
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Figure 23.  In vivo genomic footprinting of the PRDI-BF1 proximal promoter 
reveals no protein-DNA interactions in lymphoma cells treated with Trichostatin A.  
CA46 lymphoma cells were analyzed for interactions at the first 200 basepairs of the 
promoter region.  The control lanes show the in vitro methylated guanine residues, while 
the DMS lanes (Control and TSA) show the in vivo methylated residues.  No interactions 
are induced by Trichostatin A treatment at this specific region of the proximal promoter.  
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Figure 24.  Activity of the HDAC inhibitor LBH589 in Mino mantle cell lymphoma 
cells.  LBH589 induces PRDM1 gene expression and induces apoptosis in Mino mantle 
cell lymphoma cells following 24 hours of treatment.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25.  Treatment with the HDAC inhibitor SAHA decreases PRDI-BF1 mRNA 
levels in freshly isolated cells from a mantle cell lymphoma patient.  Treatment of 
patient cells for 6-20 hours with increasing doses of SAHA decreased PRDI-BF1 mRNA 
levels.   
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Figure 26.  Treatment with the proteasome inhibitor Bortezomib induces PRDI-BF1 
mRNA levels in CA46 lymphoma cells.  Treatment of CA46 lymphoma cells for 24 
hours with increasing doses of Bortezomib induces PRDI-BF1 mRNA levels.  The mean 
of 3 experiments is shown with standard deviations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27.  Treatment with the proteasome inhibitor Bortezomib induces PRDI-BF1 
mRNA levels and induces apoptosis in Mino mantle cell lymphoma cells.  Treatment 
of Mino mantle cell  lymphoma cells for 24 hours with increasing doses of Bortezomib 
induces PRDI-BF1 mRNA levels and apoptosis, as measured by Annexin V staining.  
The data shown are representative of 3 independent experiments.  
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Figure 28.  Treatment with the proteasome inhibitor Bortezomib induces PRDI-BF1 
mRNA levels in freshly isolated cells from a mantle cell lymphoma patient.  
Treatment of patient cells for 6-20 hours with increasing doses of Bortezomib induced 
PRDI-BF1 mRNA levels.  A, This patient sample was comprised of approximately 90% 
mantle cell lymphoma cells.  B, Total mantle cell lymphoma cells unknown for this 
patient sample. 
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 The proteasome inhibitor Bortezomib induced PRDM1 mRNA levels in a dose-
dependent manner in both the Mino and CA46 lymphoma cell lines.  Induction of PRDI-
BF1 mRNA levels correlates with an increase in apoptosis of these cells (figures 26 and 
27).  Fresh patient samples from lymphoma patients were treated for 6-20 hours with this 
drug and some induction was seen at lower doses.  A high dose of 50 nM in one patient 
demonstrated a decrease in PRDM1 expression, compared to the 25 nM dose (figure 28).  
This could be due to apoptosis and cell death caused by higher drug doses.  However, this 
was not examined.   
 
Human B cells differentiated to plasmablasts have increased PRDM1 mRNA levels 
 Using lymphoma and myeloma cell lines with differing levels of PRDM1 gene 
expression is one method to study the regulation of PRDM1 gene expression.  Another 
way is to utilize normal B cells capable of differentiation.  However, even though this 
procedure has been previously described (253), it was necessary to work out the proper 
conditions in our lab and determine if PRDM1 levels increased upon differentiation.  
Using peripheral blood from normal human donors, we were able to differentiate the 
purified B cells to plasmablasts expressing increased levels of PRDM1α and PRDM1β 
and reduced levels of PRDI-BF1 downstream targets CIITA promoter 3 and BSAP 
(figure 29).  On day 6 of culture, the cell yield was decreased compared to what had been 
previously described (253).  The availability of low numbers of plasmablasts at day 6 has 
limited the ability to do experiments beyond mRNA analysis at this stage.  This problem 
is currently being addressed in the lab. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29.  Purified B cells differentiated to plasmablasts have increased levels of 
PRDI-BF1 mRNA expression.  Activated B cells (day 4 of culture) have increased 
levels of CIITA promoter III and BSAP mRNA expression, while PRDI-BF1α and PRDI-
BF1β mRNA levels are not expressed.  However, upon differentiation to a plasmablast 
(day 6 of culture), PRDI-BF1α and PRDI-BF1β mRNA expression are increased, while 
the PRDI-BF1 downstream targets BSAP and CIITA promoter III are decreased.   
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Discussion 
 The transcription factor PRDI-BF1/Blimp-1 is required for the differentiation of a 
B cell to a plasma cell (237) and accomplishes this by directly repressing a number of 
downstream targets (236).  Work from our lab has demonstrated a rapid induction of 
PRDI-BF1/Blimp-1 mRNA in lymphoma cells as measured by nascent RNA levels in 
anti-IgM-stimulated cells as well as factor binding to the promoter as seen by in vivo 
DMS footprinting.  These data indicate the promoter is poised and ready for activation in 
these cells (see Chapter Two).  Very recent evidence demonstrates expression of PRDI-
BF1/Blimp-1 mRNA in a DLBCL cells (32, 195, 251).  However, PRDM1 gene 
mutations were found in approximately one quarter of all DLBCL patients studied and 
led to transcription of a nonfunctional protein (251).  The work presented in this chapter 
demonstrates a correlation between PRDM1 induction and apoptosis in both BL and 
MCL cell lines and patient samples.   
 Overexpression of c-myc is a classical hallmark of BL.  c-Myc is a direct 
downstream target of PRDI-BF1/Blimp-1 (140), so induction of PRDM1 in this type of 
lymphoma may be a way to target dysregulated cell growth and survival of these cells.  
When CA46 BL cells were treated with the HDAC inhibitor Trichostatin A, PRDM1 
expression levels increased significantly.  Exactly what the mechanism for this remains to 
be elucidated.  It could be due to decreased BCL-6 expression, which is known to repress 
PRDI-BF1 (262) and is known to be regulated by histone acetylation (13).  Another 
possible explanation is downregulation of c-myc by induction of PRDI-BF1.   
 Mantle cell lymphoma is an incurable disease characterized by high levels of 
cyclin D1 (275).  Therefore, discovery of chemotherapeutic agents which may have 
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therapeutic potential in treating this disease is of upmost importance.  The proteasome 
inhibitor has been effective alone or in combination with other drugs in the treatment of 
myeloma (120).  Its use has been extended to treatment of lymphoma patients (132).  Our 
work demonstrates the ability of Bortezomib to induce apoptosis in these cells, which 
correlates with the induction of PRDM1 gene expression.  Bortezomib was shown to 
induce the UPR in myeloma cells (184), which involves XBP.  XBP is downstream of 
PRDI-BF1, so inducing PRDM1 could affect XBP expression in these cells.  Our studies 
have been broadened to study the therapeutic potential of both Bortezomib and SAHA in 
mantle cell patient samples.  By increasing PRDM1 expression in these cells, it may be 
possible to modulate downstream target gene expression responsible for the aggressive 
phenotypes of these lymphomas.  However, our studies do not currently address the role 
of XBP in MCL upon PRDM1 induction.  Bortezomib does induce PRDM1 expression in 
patient samples tested.  However, the HDAC inhibitor SAHA decreased PRDM1 levels 
in the one patient examined (figure 25).  This does not correlate with data acquired in 
Mino cells using LBH589 (figure 24).  This could be due to this particular patient being 
unresponsive to drug treatment in general.  The current and past treatment regimens of 
the patients tested are unknown to us, as is their disease status.  Studies with both 
Bortezomib and SAHA, or other HDAC inhibitors, will need to be extended to a greater 
number of patients.   
 Cyclin D1 is not one of the known direct targets of PRDI-BF1 repression.  In 
normal plasma cells, which express high levels of PRDI-BF1, microarray data 
demonstrates absence of the cyclin D1 gene CCND1 expression (48).  Analysis of the 
cyclin D1 promoter indicates there are at least three putative PRDI-BF1 binding sites.  
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One possible mechanism for apoptosis seen in drug-treated MCL cells is PRDI-BF1-
mediated repression of cyclin D1 promoter activity.  Cyclin D1 is important in cell cycle 
progression and, as such, repression of its activity could cause growth arrest and 
apoptosis.  Analyzing the role PRDI-BF1 plays in cyclin D1 repression would provide 
further insight into how MCL cells may die upon drug treatment. 
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Materials and Methods 
 
Cell lines and drugs 
 The CA46 Burkitt’s lymphoma cell line, Mino mantle cell lymphoma line, and 
U266 myeloma cell lines were maintained in RPMI medium (Invitrogen) supplemented 
with 10% fetal bovine serum (FBS) (HyClone), and 1% penicillin/streptomycin (P/S) 
(Invitrogen).  The HDAC inhibitor Trichostatin A (Sigma) was dissolved in 100% 
ethanol and used at a concentration of 100 ng/ml.  The Novartis HDAC inhibitor 
LBH589 was obtained from Dr. K. Bhalla (Moffitt Cancer Center), while the proteasome 
inhibitor Bortezomib was obtained from Dr. W.S. Dalton (Moffitt Cancer Center).   
 
Apoptosis assay  
 Cells were treated with either Trichostatin A, SAHA, LBH589, or Bortezomib as 
denoted, followed by Annexin V-PE and 7-AAD staining per manufacturer’s protocol 
(BD Pharmingen).  Flow cytometry acquisition was done using a FACSCalibur and data 
was analyzed with CellQuest software (Becton Dickinson, Carpinteria, CA).   
 
Real-time PCR 
 RNA was isolated from cells using TriZol reagent (Invitrogen) and the 
manufacturer’s protocol.  One µg RNA was DNase-treated using RQ1 DNase (Promega), 
followed by first-strand cDNA synthesis using the iScript cDNA synthesis kit (Bio-Rad).  
1/20th of the final cDNA reaction volume was used in each PCR reaction.  Primers 
sequences are as follows:  PRDI-BF1 FWD, 5’- TACATACCAAAGGGCACACG -3’, 
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PRDI-BF1 REV, 5’- TGAAGCTCCCCTCTGGAATA -3’, CIITA promoter 3 FWD, 5’- 
CAATGCGTTGCCTGGCTC -3’, CIITA promoter 3 REV, 5’- 
GCTGTTAAGAAGCTCCAGGTAG 3’, BSAP FWD, 5’- 
TGGAGGATCCAAACCAAAGG -3’, BSAP REV, 5’- 
GGCAAACATGGTGGGATTTT -3’, GAPDH FWD, 5’- 
GAAGGTGAAGGTCGGAGT -3’, GAPDH REV, 5’- GAAGATGGTGATGGGATTTC 
-3’.  PRDI-BF1, CIITA promoter 3, and GAPDH primer sets were run using an annealing 
temperature of 60oC, while the BSAP primer set was run using an annealing temperature 
of 55oC.  Real-time PCR reactions were performed in a volume of 25 µl, which included 
200 nM of each forward and reverse primer and iQ  SYBR Green Supermix (Bio-Rad).  
Reactions were run in duplicate using an iCycler and iQ software Version 1.0 (Bio-Rad).  
Average threshold cycles (Ct) for the genes of interest were normalized to the average 
GAPDH Ct values for each cDNA sample and relative levels of the genes of interest were 
calculated by the ∆∆Ct method (145):  for example, 2-(PRDI-BF1-GAPDH) for PRDI-BF1 gene 
expression. 
 
B cell isolation and differentiation to plasmablasts 
 Peripheral blood B cells were obtained from healthy donors and differentiated to 
plasmablasts, as previously described (253).  Briefly, B cells were purified from 
peripheral blood lymphocytes by positive selection with anti-CD19 MACS Microbeads 
(Miltenyi) or negative selection with the human B cell isolation kit II (Miltenyi) using the 
AutoMACS magnetic bead sorter (Miltenyi).  Purification and cell viabiltiy was verified 
by staining cells with CD19-PE (BD Pharmingen) and 2 nM ToPro3 (Invitrogen) and 
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analyzing for viable CD19+ B cells using the FACSCalibur.  Purified B cells were plated 
on irradiated CD40L cells (71) and treated with IL-2 (20 U/ml), IL-4 (50 ng/ml), IL-10 
(50 ng/ml), and IL-12 (2 ng/ml) (Peprotech) in RPMI supplemented with 10% FBS and 
1% P/S for 4 days.  The activated B cells were gently detached from the CD40L cells and 
washed three times with complete medium and grown an additional 2 days in complete 
medium supplemented with IL-2 (20 U/ml), IL-6 (5 ng/ml), IL-10 (50 ng/ml), and IL-12 
(2 ng/ml) (Peprotech).  On day 6 of culture, cells were stained with CD20-FITC, CD38-
APC, and 7-AAD, and plasmablasts were sorted out by selecting CD20-/CD38+ viable 
cells on the FACSAria cell sorter.  RNA was collected and analyzed by real-time PCR.   
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Chapter Four 
 
The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces 
apoptosis in drug-resistant myeloma cells 
 
Introduction 
 
Multiple myeloma is a fatal plasma cell malignancy characterized by the 
accumulation of latent plasma cells in the bone marrow (84).  Numerous investigators 
have examined the frequency of ras mutations in multiple myeloma, and have reported a 
correlation between activating ras mutations and disease progression (144, 178, 204).  
Furthermore, Rowley et al. demonstrated that ANBL6 myeloma cells transfected with 
activated N- or K-Ras were more resistant to apoptosis induced by dexamethasone, 
doxorubicin, and melphalan, suggesting a role for Ras mutations in resistance to 
chemotherapeutic drugs (216).  Following initial response to therapy, patients with 
multiple myeloma invariably relapse and are refractory to additional treatment regimens.  
Thus, myeloma has long served as a model system for investigation of the drug resistant 
phenotype.  These model systems have led to the characterization of several mechanisms 
of resistance, including overexpression of the anti-apoptotic protein, Bcl-xL (261); 
induced expression of the ATP dependent efflux pump P-glycoprotein (44); and altered 
expression of topoisomerases (68).   
The Ras oncoprotein is a small G-protein signal tranducer that requires a prenyl 
lipid modification and membrane association for signal transduction activity (85, 280). 
Two enzymes, farnesyltransferase (FTase) and geranylgeranyltransferase I (GGTase I), 
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catalyze this prenyl posttranslational modification by transferring farnesyl or 
geranylgeranyl to the cysteine of the carboxyl terminal CAAX (C=cysteine, A=aliphatic, 
X=any amino acid).  H-, N-, and K-Ras are all farnesylated.  When FTase is inhibited, K-
Ras, but not N-Ras or H-Ras, becomes geranylgeranylated (133).  Because prenylation is 
required for the oncogenic activity of Ras, we, and others designed FTase and GGTase I 
inhibitors as potential anticancer drugs (228).  To date, the majority of studies using 
prenylation inhibitors have focused on solid tumors, including lung, bladder, breast, and 
colon carcinomas (14, 133, 246, 247).  In this study, we examined the activity of 
prenylation inhibitors in myeloma cell lines with different Ras mutation status, using the 
CAAX peptidomimetics FTI-277 (273) and GGTI-2166 (245).  These inhibitors are 
structural analogues based on the tertiary structure of the CAAX tetrapeptide (228).  
Cytotoxicity and growth inhibition were examined for correlation with inhibition of Ras 
protein processing.  In addition, myeloma cell lines with well-characterized mechanisms 
of drug resistance were analyzed for response to farnesyltransferase inhibitors (FTI).  No 
cross-resistance to FTI was identified in myeloma cells selected for resistance to 
doxorubicin or melphalan, nor did forced constitutive overexpression of Bcl-xL confer 
resistance to FTI.  These studies provide support for further pre-clinical and clinical trials 
with prenylation inhibitors in drug resistant myeloma.   
 
Results 
Myeloma cells with a N-Ras mutation are highly sensitive to FTI-277 
We used MTT and clonogenic assays to determine the sensitivity of myeloma 
cells to growth inhibition by FTI-277.  The MTT assay measures the metabolic activity of 
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cells, while the soft agar clonogenic assay assesses the ability of cells to divide and form 
colonies in an anchorage-independent fashion.  H929 cells, which express activated N-
Ras, were found to be significantly more sensitive to growth inhibition by FTI-277 than 
either U266 cells, which express wild-type Ras, or 8226 cells, which express activated K-
Ras (figure 30A).  The 8226 cell line was three times more resistant to the growth 
inhibitory activity of FTI-277 than H929 cells (IC50 41.6 µM vs. IC50 12.7 µM), while 
U266 cells demonstrated an intermediate sensitivity (IC50 25.4 µM).  Soft agar 
clonogenic assays demonstrated a similar pattern of sensitivity, with H929 cells more 
sensitive to treatment with FTI-277 than 8226 cells with activated K-Ras over all doses 
(p<0.05, Student’s t-test) (figure 30B).  Neither mutant N- nor K-ras containing cells 
were significantly different in sensitivity to FTI-277 compared to the wild-type ras U266 
cells.  Because prenylation inhibitors are generally considered to be cytostatic agents, we 
also examined the ability of FTI-277 to induce apoptosis in myeloma cells.  Myeloma 
cells were treated with FTI-277 for 48 h, followed by staining with Annexin V-FITC and 
flow cytometry analysis.  In correlation with the growth inhibition assays, a dose 
dependent response was demonstrated, with greatest cell death in the N-Ras mutant H929 
cells, followed by the wild-type U266 cells.  Similar to the growth inhibition and 
clonogenic analysis, the K-ras mutant 8226 cell line was found to be the least sensitive to 
FTI cytotoxicity (figure 30C).  These data are also compatible with previous reports, in 
which tumor cells of epithelial origin with activated K-Ras were shown to be less 
responsive to FTI treatment compared to cells with activated N-Ras or wild-type Ras (6, 
59). 
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Figure 30.  Myeloma cells with activated N-Ras mutation are more sensitive to 
cytotoxicity by FTI-277 compared to cells with wild-type Ras or K-Ras mutation.  A,  
Myeloma cells were treated with FTI-277 continuously for 96 hours and assayed using 
the MTT cytotoxicity assay.  IC50s were calculated by linear regression of percent 
survival versus log drug concentration and 95% confidence intervals were determined by 
statistical analysis.  Data shown are a minimum of three independent experiments, and 
summarized with the Ras mutation status, corresponding regression estimate of the IC50, 
and 95% confidence intervals.  B, H929, U266, or 8226 cells were treated with vehicle 
(DTT/DMSO), 5 µM, 10 µM, or 15 µM FTI-277 and grown in 0.3% agar layered over 
0.6% agar.  Colonies were stained with MTT dye and quantitated by counting.  H929 
cells with activated N-Ras were significantly more sensitive to FTI-277 treatment over all 
doses than 8226 cells with activated K-Ras (p<0.05).  The data are represented as mean 
percent survival above control and are the mean of a minimum of five independent 
experiments done in triplicate.  The table summarizes 95% confidence intervals for a 
comparison of two cell lines.  (* indicates statistical significance by regression analysis.)  
C,  Myeloma cells were treated for 48 hours with 5-30 µM FTI-277, then assayed for 
apoptosis using Annexin V-FITC staining as determined by flow cytometry.  FTI-277 
caused apoptosis in myeloma cells in a dose-dependent manner, with N-Ras mutated 
H929 cells being most sensitive to FTI-277-induced apoptosis.  The data are represented 
as percent apoptosis above control and are the mean of a minimum of three independent 
experiments. 
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Inhibition of Ras processing and relationship to FTI-induced apoptosis 
To determine if there was a correlation between inhibition of Ras processing and 
either growth inhibition or apoptosis, we examined the ability of FTI-277 to block Ras 
prenylation in the myeloma cell lines.  Lipid modification of the p21 Ras protein alters 
the protein mobility on SDS-PAGE, resulting in a shift to a lower apparent molecular 
weight on Western blots and allowing detection of intracellular drug activity.  Although 
FTI-277 demonstrates greater toxicity in the H929 cell line, inhibition of N-Ras 
processing is more effective in the U266 cells compared to H929 cells even when treated 
with doses as low as 1.25 µM FTI-277 (figure 31).  Additionally, N-Ras processing in 
U266 cells is inhibited at much lower doses (range:  1.25-10 µM FTI-277) than that 
required for induction of apoptosis (15-30 µM FTI-277), suggesting that the mechanism 
by which FTI-277 induces apoptosis in U266 most likely does not involve inhibition of 
the prenylation and function of N-Ras.   
Processing of K-Ras in the 8226 cells was completely unaffected by any dose of 
FTI-277 up to 30 µM following 48 hour treatment.  Because K-Ras becomes 
geranylgeranylated when FTase is inhibited (133, 278),  we also examined K-Ras 
prenylation following exposure to the geranylgeranyltransferase inhibitor, GGTI-2166, 
either alone or in combination with FTI-277.  No effect was seen with either FTI-277 or 
GGTI-2166 alone (figure 31C).  When 8226 cells were treated simultaneously with FTI-
277 and GGTI-2166 for 48 hours, inhibition of K-Ras processing occurs in a dose-
dependent manner.  Maximal response for inhibiting K-Ras processing occurred at 5 µM 
GGTI-2166 in combination with 10 µM FTI-277 (figure 31D).   
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Figure 31.  FTI-277 inhibits N-Ras processing in myeloma cells with wild-type Ras 
(U266) and activated N-Ras (H929), while both FTI-277 and GGTI-2166 inhibit K-
Ras processing.  Myeloma cells were treated with FTI-277 for 48 hours.  Inhibition of 
Ras processing was demonstrated by a band shift to a higher apparent molecular weight 
by Western blot analysis (U, unprocessed Ras, P, processed Ras).  A, N-Ras processing 
of H929 cells following treatment with 0 (vehicle control), 1.25, 2.5, 5, or 10 µM FTI-
277 for 48 hours.  B, N-Ras processing of U266 cells following treatment with 0 (vehicle 
control), 1.25, 2.5, 5, or 10 µM FTI-277 for 48 hours.  C, K-Ras processing of 8226 cells 
following treatment with 0 (vehicle control), 5, 10, 15, or 30 µM FTI-277, and 5 or 10 
µM GGTI-2166 for 48 hours.  D, K-Ras processing of 8226 cells following treatment 
with 0 (vehicle control), 5 µM GGTI-2166 plus 5-30 µM FTI-277 or 10 µM GGTI-2166 
plus 5-30 µM FTI-277 for 48 hours.  Equal loading was determined by immunoblotting 
with β-actin (data not shown). 
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Co-treatment of the 8226 cell line with FTI-277 and GGTI-2166 also 
demonstrated an enhanced apoptotic response above the levels for each drug alone.  8226 
cells treated with 30 µM FTI-277 alone induced approximately 12% drug-specific 
apoptosis, while GGTI-2166 treatment alone was completely ineffective in these cells.  
However, the combination of 10 µM GGTI-2166 with FTI-277 increased the cell death 
two-fold compared to FTI-277 alone in both MTT growth inhibition and Annexin V 
apoptosis assays (figure 32).  Statistical analysis using linear regression with integrated 
and reduced models demonstrated that growth inhibition and apoptosis following co-
treatment with FTI-277 and GGTI-2166 occurs in an additive manner.  These data are 
compatible with previous studies demonstrating that inhibition of farnesyl transferase is 
insufficient to affect K-ras processing, and concomitant inhibition of geranylgeranyl 
transferase is required.  Furthermore, inhibition of N-Ras processing in H929 and U266 
cells occurs at doses well below those necessary to cause growth inhibition and apoptosis, 
while inhibition of K-Ras processing and significant apoptosis in 8226 cells requires co-
treatment with FTI-277 and GGTI-2166.  
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Figure 32.  Both FTI-277 and GGTI-2166 inhibit K-Ras processing.  A, Myeloma 
cells were treated for 48 hours with 5-30 µM FTI-277 alone, 5-10 µM GGTI-2166 alone, 
or 10 µM GGTI-2166 combined with 30 µM FTI-277, then assayed for apoptosis using 
Annexin V-FITC staining by flow cytometry.  FTI-277 caused apoptosis of 8226 
myeloma cells in a dose-dependent manner, while GGTI-2166 had no effect on the cells.  
A combination of FTI-277 and GGTI-2166 had an additive effect on inducing apoptosis 
in 8226 cells.  The data are represented as percent apoptosis above control and are the 
mean of a minimum of three independent experiments.  B, Myeloma cells were treated 
with FTI-277 alone, FTI-277 plus 5 µM GGTI-2166, or FTI-277 plus 10 µM GGTI-2166 
for 96 hours, then assayed using the MTT cytotoxicity assay.  Increasing the dose of 
GGTI-2166 enhanced the cytotoxic effect above that of FTI-277 treatment alone.  The 
data are represented as percent survival above control cells.  The data are the mean of 
three independent experiments done in quadruplicate. 
 
 
Bcl-xL and classical mechanisms of drug resistance are not determinants of 
resistance to FTI-277.  The anti-apoptotic protein Bcl-xL is a known determinant of drug 
resistance in multiple myeloma and has previously been shown to protect myeloma cells 
from cytotoxic drugs including doxorubicin, melphalan, mitoxantrone, and VP-16 (189). 
We explored the ability of FTI-277 to induce apoptosis in myeloma cells overexpressing 
Bcl-xL.  Using U266 cells engineered to constitutively overexpress Bcl-xL (U266/Bcl-xl), 
we compared the cytotoxic activity of FTI-277 in U266 cells expressing low basal levels 
of Bcl-xL (U266 and U266/Neo) to those overexpressing Bcl-xL (figure 33A-B).  Using 
both MTT cytotoxicity and CMXRos/Annexin V apoptosis assays, no significant 
difference was found in the response to FTI-277 between the cells expressing low levels 
of Bcl-xL and those with high constitutive expression.  Bcl-xL has been shown to prevent 
cell death by preventing the release of cytochrome c and mitochondrial perturbation 
(222).  Equal sensitivity of cells expressing varying levels of Bcl-xL indicate that 
apoptosis induced by the FTIs in myeloma cells occurs through a mitochondrial-
independent mechanism.  Furthermore, the observation that Bcl-xL does not confer 
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resistance to prenylation inhibitors supports the use of these agents in patients with drug 
resistant disease.   
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 Figure 33.  Bcl-xL is not a determinant of resistance to FTI-277.  A, U266, U266/Neo, and U266/Bclxl cells were treated with FTI-
277 continuously for 96 h and assayed for cytotoxicity using the MTT assay. IC50s were calculated and the 95% confidence intervals 
estimated by linear regression of percent survival vs log drug concentration. The data shown are of three independent experiments 
done in quadruplicate. The corresponding table summarizes the IC50 estimate and 95% confidence intervals from linear regression for 
the U266 cell lines.  B, Bcl-XL protein expression. The myeloma cell lines H929, U266, U266/Neo and 8226 express minimal levels 
of endogenous Bcl-XL protein relative to the overexpressing transfectant, U266/Bcl-xl. Equal loading was determined by 
immunoblotting for β-actin.  C, U266, U266/Neo, and U266/Bcl-xl cells were treated with FTI-277 continuously for 48 hours and 
assayed for apoptosis using CMXRos (Chloromethyl-X-Rosamine)/Annexin-V staining. Loss of MMP and Annexin-V staining of cell 
surface phosphatidylserine are independent markers of apoptosis, therefore viable cells appear in the upper left quadrant of the flow 
cytometry dot plot, while the other three quadrants represent cells in various stages of apoptosis. There is no significant difference in 
apoptosis in the U266 and U266/Bcl-xl cell lines, indicating that Bcl-xL protein overexpression in U266 cells is not a determinant of 
resistance to FTI-277 in U266 myeloma cells. The data shown are representative of three individual experiments. 
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Patients with multiple myeloma frequently relapse with multi-drug resistant 
disease, and myeloma cells selected in vitro for resistance to chemotherapeutic drugs 
provide a model for examining mechanisms of acquired drug resistance.  We utilized 
cells selected for resistance to doxorubicin, in the presence (68) or absence (44) of the 
calcium channel blocker, verapamil, and cells selected for resistance to melphalan (11) 
for cross resistance to FTI-277.  No significant differences were found in the response of 
the parental cells, 8226/S, as compared to the drug resistant variants, 8226/Dox40, 
8226/Dox1V, or 8226/LR5 (figure 34).  The 8226/Dox40 cell line has been shown to 
overexpress the ATP-dependent efflux pump, P-glycoprotein, and is approximately 180-
fold resistant to doxorubicin.  Additionally, this cell line demonstrates cross-resistance to 
mitoxantrone, etoposide, and vincristine (44).  However, no cross-resistance to FTI-277 
was demonstrated, indicating that the prenylation inhibitor is not a substrate for P-
glycoprotein efflux.  Additionally, 8226 drug resistant cells with other mechanisms of 
drug resistance, such as altered topoisomerase II activity and elevated levels of 
intracellular glutathione, are also not significantly more resistant to treatment with FTI-
277 compared to parental cells.  These data support the potential utility of FTI inhibitors 
in relapsed myeloma patients, either as single agents, or in combination with standard 
chemotherapeutic drugs.  
 
  
 
 
Cell line IC50 (uM) 95% CI
8226 36 30-42
8226/Dox40 40.5 30.8-50.3
8226/Dox1V 23.9 17.9-29.8
8226/LR5 38 30.8-45.3
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Figure 34.  Drug-resistant myeloma cells are not cross-resistant to FTI-277.  8226/S, 
8226/Dox40, 8226/Dox1V, and 8226/LR5 were treated with FTI-277 continuously for 96 
hours and assayed using the MTT cytotoxicity assay.  IC50s were calculated by linear 
regression of percent survival versus log drug concentration and 95% confidence 
intervals were determined by statistical analysis.  The IC50 estimates from linear 
regression were calculated from three independent experiments done in quadruplicate.  
The table summarizes the IC50s and 95% confidence intervals for the myeloma cell lines. 
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Discussion 
Ras mutations are among the most common oncogenic mutations identified in 
many malignant diseases, including multiple myeloma.  Prenylation inhibitors are a new 
class of agents developed to inhibit Ras protein processing and prevent constitutive signal 
transduction by the activated protein.  Clinical trials with FTIs have demonstrated a 
therapeutic response in leukemia patients, even though Ras mutation status was not a 
determinant for clinical response (6, 114).  Similarly, preclinical studies using solid 
tumor xenografts have not supported a correlation of response with Ras mutation status 
(6, 59).  Thus, the biologic basis for FTI activity in tumor cells is yet to be fully defined.   
In this study we examined the cytotoxic activity and inhibition of Ras processing 
in three myeloma cell lines with differing Ras mutation status.  The U266 cell line, which 
expresses wild type Ras, is the most sensitive to inhibition of Ras processing; however, 
these cells are not sensitive to FTI-mediated cytotoxicity.  The H929 cell line, which 
expresses mutant N-ras, demonstrates an intermediate sensitivity to FTI-277-induced 
inhibition of N-Ras processing, but is the most sensitive to growth inhibition and 
apoptosis.  In all assays, the 8226 cell line containing a K-ras mutation is the most 
resistant to the cytotoxic effects of FTI.  Similar to previous studies in epithelial 
carcinomas, K-Ras processing could only be inhibited with a combination of FTI and 
GGTI in 8226 cells.  In a study by Lerner et. al, pancreatic, bladder, and pulmonary 
tumor cells also demonstrated resistance to inhibition of K-Ras processing when treated 
with FTI-277 or GGTI-298 alone (133).  Furthermore, inhibition of K-Ras processing in 
these cell lines did not correlate with growth inhibition as measured by soft agar 
clonogenic assays.  In contrast, in this study the most sensitive cell line is the one with N-
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Ras mutation suggesting that N-Ras mutation status may be a determinant of response.  
Consistent with this is the fact that the IC50 for growth inhibition is similar to that of 
inhibition of N-Ras processing in H929 but not in U266.  In U266, inhibition of N-Ras 
processing (IC50=2 µM) does not result in inhibition of growth (see Figure 31).   
Expression of the anti-apoptotic protein Bcl-xL has been shown to contribute to 
resistance to a broad range of chemotherapeutic agents in myeloma cells (189, 261).  
However, the data presented here demonstrates that FTI-277 is effective in myeloma cells 
in vitro independent of Bcl-xL expression.  The U266 myeloma cell line expresses a basal 
level of Bcl-xL, that confers resistance to both Fas and chemotherapeutic agents (31, 189).  
In contrast, H929 myeloma cells express low levels of Bcl-xL and are more sensitive to 
the cytotoxicity of the FTIs.  This observation led us to examine FTI activity in U266 
myeloma cells engineered to express very high levels of Bcl-xL (31).  In these myeloma 
cell lines, Bcl-xL expression had no effect on the cytotoxicity of the FTI.  These data are 
in contrast to a previous study demonstrating resistance to the farnesyltransferase 
inhibitor L-739,749 by Bcl-xL overexpression in Rat1 cells (126).  This discrepancy is 
most likely due to the different cell types and their relative dependence on Bcl-xL for 
survival.   
Classical mechanisms of acquired drug resistance include increased expression of 
drug efflux proteins such as P-glycoprotein, reduced expression of intracellular drug 
targets, such as topoisomerase II (68), and enhanced drug detoxification by glutathione S-
transferase (11).  The novel observation that these classical mediators of drug resistance 
do not confer cross-resistance to FTI-277 provides strong rationale for clinical trials of 
FTI in myeloma patients that are refractory to standard chemotherapeutic agents.   
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Therapeutic agents with molecular targets provide a unique opportunity to 
specifically inhibit malignant growth with minimal systemic toxicity.  Many of these 
agents are being extensively investigated as potential combination therapies, and in fact, 
previous studies using a xenograft model have demonstrated that FTI in combination with 
cisplatin, taxol, or gemcitabine is more effective than either agent alone (245).  Our data 
demonstrate that farnesyl transferase inhibitors inhibit growth and induce apoptosis in 
both drug sensitive and drug resistant myeloma cells in vitro.  These results support 
ongoing clinical studies in myeloma patients, and may contribute to the development of a 
novel treatment for this incurable disease.  Recently, phase II clinical trial data has 
demonstrated stabilization of disease in over 60% of myeloma patients treated with the 
FTI Zarnestra (3). 
 
Materials and Methods 
 
Cell lines and drugs 
 The RPMI 8226, U266, and H929 multiple myeloma cell lines were maintained in 
RPMI medium (CellGro, MediaTech, Herndon, VA) supplemented with 5% or 10% fetal 
bovine serum (FBS) (Omega Scientific, Tarzana, CA), 1% penicillin/streptomycin (P/S), 
and 100 mM L-glutamine (Gemini Bio-Products, Calabasas, CA).  The H929 cell line 
was also supplemented with 0.05 M 2-mercaptoethanol (Sigma, St. Louis, MO).  U266 
cells transfected with Bcl-xL were cloned and selected for high (U266/Bcl-xl) or low 
(U266/Neo) Bcl-xL protein expression and have been previously described (189).  The 
drug resistant cell lines, 8226/Dox40 (44), 8226/Dox1V (68), and 8226/LR5 (11) have all 
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been previously described.  The farnesyltransferase inhibitor (FTI)-277 (273) and 
geranylgeranyltransferase inhibitor (GGTI)-2166 (245) were initially dissolved in 10 mM 
dithiothreitol in dimethyl sulfoxide (DTT/DMSO) and diluted to the appropriate 
concentrations with RPMI complete medium. 
 
MTT cytotoxicity assay   
 Cells were seeded at 8000-14000 cells/well in 96-well plates (Becton Dickinson, 
Lincoln Park, NJ).  To establish a dose-response to FTI-277, cells were incubated 96 
hours in two-fold serial dilutions ranging from 3.75x10-7 M to 1x10-5 M.  Following 
continuous drug exposure, 50 µl 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide (MTT) dye was added.  The insoluble formazan complex was solubilized with 
DMSO and absorbance measured at 540 nm.  IC50s and 95% confidence intervals were 
calculated by regression analysis of the linear portion of the dose-response curve.  
 
Soft agar clonogenic assay 
 Cells were seeded at densities established for optimal cloning efficiency (range: 
24000-30000 cells per well) and grown in 0.3% agar (Difco, Detroit, MI) layered over 
0.6% agar.  FTI-277 or vehicle control (10 mM DTT/DMSO) was included in the 0.3% 
agar layer of cells.  Approximately 2-3 weeks after plating, colonies were stained with 1 
mg/ml MTT and counted.   
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Ras processing assay  
 Cells were treated with FTI-277, GGTI-2166, or combinations thereof for 48 
hours.  Following drug exposure, cells were washed in PBS and lysed in a buffer 
containing 30 mM HEPES, pH 7.5, 10 mM NaCl, 1% Triton X-100, 10% glycerol, 5 mM 
MgCl2, 1 mM EGTA, 25 mM NaF, 25 µg/ml leupeptin, 2 mM 
phenylmethylsulfonylfluoride (PMSF), 2 mM sodium orthovanadate, 10 µg/ml soybean 
trypsin inhibitor, and 10 µg/ml aprotinin.  The lysates were cleared and total protein was 
determined by the Bradford assay (Bio-Rad, Hercules, CA).  Equal amounts of protein 
(50 µg) were separated on 12.5% SDS-PAGE and transferred to PVDF membrane (Bio-
Rad).  Membranes were probed with polyclonal antisera specific for N- or K-Ras (Santa 
Cruz Biotechnology, Santa Cruz, CA), Bcl-xL (Pharmingen, San Diego, CA), or 
monoclonal antiserum specific for β-actin (Sigma, St. Louis, MO), followed by detection 
with chemiluminescence (Roche, Indianapolis, IN).   
 
Apoptosis assays  
 Cells were treated with FTI-277 and/or GGTI-2166 for 48 hours continuously, 
followed by Annexin V-FITC staining according to the manufacturer's protocol 
(BioVision, Mountain View, CA).  In experiments that included CMXRos staining for 
mitochondrial perturbation, cells were incubated for ½ hour prior to collection with 200 
nM CMXRos (Molecular Probes, Eugene OR).  Flow cytometry acquisition was done on 
a FACSCalibur and analyzed with CellQuest software (Becton Dickinson, Carpinteria, 
CA). 
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Statistical analysis 
IC50 values were calculated and 95% confidence intervals were estimated using a 
simple linear regression analysis following logistic transformation of the response 
variable where applicable.  Differences across cell lines or doses were tested using either 
the Student’s t-test or Wilcoxon Rank Sum test.  Differences in the mean of the 
transformed responses were determined by 95% confidence intervals.  In the combination 
FTI-277/GGTI-2166 study, a linear regression analysis was used to test for synergism 
and additivity across dose levels. 
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Chapter Five 
General Discussion 
 
 The work presented in this dissertation provides insight into the regulation of the 
human PRDM1 gene and explores the possibility of modulating PRDM1 gene expression 
as a target for inducing apoptosis of lymphoma cells.  Very little was known as to the 
regulation of PRDI-BF1 upon initiation of this project.  The finding that regulation of this 
gene occurs primarily at the transcriptional level is very novel.  It is also at the foundation 
of preliminary data presented here demonstrating induction of PRDM1 by 
chemotherapeutic agents both in cell lines and patient samples.  This induction correlates 
with a dose-dependent increase of apoptosis, suggesting the possibility PRDI-BF1 may 
play an important role in more than just differentiation.   
 PRDI-BF1 was traditionally thought to play a role in the differentiation from a B 
cell to a plasma cell.  However, since inception of this project, PRDI-BF1 has been 
shown to be expressed by a number of organisms at different stages of development as 
well as in cells where it was originally thought to not be expressed, such as T cells (111) 
and B cells of myeloma patients (21).  These findings are intriguing and lead to many 
more questions as to the role PRDM1 might play here.   
 The finding that the PRDI-BF1 promoter is loaded with factors in lymphoma cells 
is a very interesting one, as one would anticipate a bare promoter in a cell which does not 
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express this gene.  However, when taken with the data demonstrating the rapid induction 
of the transcriptional activation, as is seen in figure 9 with 1 hour anti-IgM treatment, it 
indicates the PRDI-BF1 promoter is poised and primed for activation.  PU.1 is shown to 
be a factor involved in anti-IgM-induced activation of the promoter, but is definitely not 
the sole factor involved in this rapid induction of transcriptional activity, as is seen by 
data presented in figures 19 and 20.  Further elucidation of the roles played by the PI3K 
and MAPK signaling pathways may reveal additional factors involved in regulating 
PRDI-BF1.  Utilizing the chromatin immunoprecipitation assay (ChIP) in these cells 
could also be a useful tool for analyzing potential candidate factors as to their role in 
regulating the PRDM1 promoter as well as identifying chromatin modifications involved 
in promoter regulation.  However, this assay is very difficult to do in B cells and is 
currently being optimized in our lab. 
 Luciferase activity was shown to be high in myeloma cells, but is overall much 
lower in lymphoma cells.  These data agree with the expression pattern of PRDM1 in 
lymphoma and myeloma cells.  However, factors required for activation are present in 
these cells, as demonstrated by the rapid induction of nascent RNA production in 
lymphoma cells (figure 9).  There is one distal region of activation common to both 
lymphoma and myeloma cells and an additional region specific to only myeloma cells.  
These regions were further analyzed by DMS in vivo footprinting to identify putative 
factors responsible for promoter activity in both cell types.  Each of these approximately 
400 bp regions were extensively analyzed for unique contacts, but only three factor 
binding sites were eventually identified.   
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 The proximal promoter was loaded with factors in both lymphoma and myeloma 
cells (figure 11), however there were no distinct differences observed between the cell 
types.  There was a completely protected site in both cell types which was later verified 
to be a Sp1 binding site (figure 12).  However, because there were no cell-type specific 
DNA-protein interactions in this region of the promoter, we further analyzed the distal 
promoter regions of activation. 
 Analysis of the distal promoter regions revealed several factors unique to either 
lymphoma or myeloma cells.  However, upon further examination, only the PU.1 binding 
site was demonstrated to be functionally relevant to promoter activity, as shown by site-
directed mutagenesis (figures 15 and 16).  Using a footprinting technique specific for 
residues other than guanine may be helpful in identifying additional DNA-protein 
interactions which may be functionally relevant for promoter activity.  Myeloma cells 
had one unique distal region of activation, as measured by luciferase assay.  However, no 
contacts were detected in this region by DMS in vivo footprinting.  Using one 
footprinting method may have limited our ability to detect protein-DNA interactions.   
 PU.1 was found to bind the PRDI-BF1 promoter in a cell-type specific manner.  It 
is a B cell specific factor and was found to only play a role in promoter activity of 
lymphoma cells, but not myeloma cells.  It is not expressed in myeloma cells, but 
promoter activity was found to also be increased two-fold in the same distal region of the 
promoter in these cells (figure 10).  This indicates another as yet undetermined factor is 
important for increased promoter activity in myeloma cells.  This undetermined factor 
also binds a site other than site P.H, as gel shift analysis did not demonstrate occupancy 
of this site in myeloma cells (figure 17).  Since PRDM1 gene expression is elevated in 
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myeloma cells, this factor may also be one which is ubiquitously expressed in plasma-
like cells, but not B cells.   
 Because PU.1 has been known to bind promoters in complex with IRF family 
members (58, 61), we examined whether the IRF family members IRF-4 or IRF-8 were 
binding to site P.H in complex with PU.1 (figure 17 and 18).  IRF-8 has been shown to 
induce Blimp-1 expression in myeloid cells (252), while IRF-4 has been shown to be 
required for plasma cell differentiation (28).  Competition with antibodies to either IRF-4 
or IRF-8 did not affect P.H binding to DNA, indicating these factors do not appear to 
bind site P.H in complex with PU.1.   
 Work presented in Chapter Two is the first of its kind to directly link anti-IgM 
mediated B cell receptor activation to expression of PRDI-BF1/Blimp-1.  It also 
demonstrates regulation of PRDI-BF1/Blimp-1 occurs primarily at the level of 
transcription.  The promoter is poised and ready for activation, which is a significant 
finding in light of the preliminary data presented in Chapter Three, demonstrating the 
induction of PRDM1 gene expression levels PRDM1-negative lymphoma cells in parallel 
with induction of apoptosis.  However, there is no direct link between induction of 
PRDMI-BF1/Blimp-1 and induction of apoptosis.  This could be due to an indirect effect.  
It has previously been shown introduction of PRDI-BF1 is able to induce apoptosis in 
cells (164), so one could hypothesize that there is a direct link between induction of 
PRDI-BF1/Blimp-1 and induction of apoptosis.  Introduction of PRDI-BF1 into 
lymphoma cells and measuring apoptosis is the direct approach that would answer this 
question.  However, B cells are very difficult to transfect using methods other than 
electroporation.  Electroporation causes a large amount of background cell death, which 
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makes a study of apoptosis caused by introduction of PRDI-BF1 difficult.  These studies 
are currently the focus of our lab, as this is a critical question that remains to be 
answered. 
 Work presented in Chapter Four focuses on myeloma cells and the ability of the 
farnesyl transferase inhibitor, FTI-277, to induce apoptosis.  The goal of this study was to 
determine whether Ras mutation status correlated with induction of apoptosis in several 
myeloma cells with differing Ras mutation status.  Protein prenylation has been shown to 
be required for oncogenic activity of activated Ras, therefore using an inhibitor which 
blocks the transfer of the prenyl group to Ras itself would diminish its oncogenic activity.  
Our data demonstrate greatest inhibition of Ras processing in U266 myeloma cells with 
wild-type Ras, while they are not sensitive to FTI-mediated cytotoxicity, as measured by 
MTT assay and soft agar clonogenic assay.  However, H929 myeloma cells with mutated 
N-Ras were most sensitive to treatment with FTI, but demonstrated intermediate 
sensitivity to FTI-277-induced inhibition of Ras processing.  Inhibition of mutant K-Ras 
processing in 8226 myeloma cells was only accomplished by a combination of FTI-277 
and GGTI-2198, which correlates with findings in epithelial cell lines (133).  These 
findings indicate N-Ras mutation status might be a determinant of response to FTI 
treatment in myeloma patients, as the cell line harboring the N-Ras mutation was most 
sensitive to FTI-277 treatment.   
 Drug resistance is a common problem in myeloma patients, therefore it is 
important to study the effectiveness of new drugs in both drug-sensitive and drug-
resistant cell lines.  The anti-apoptotic protein Bcl-xL has been shown to confer resistance 
to chemotherapeutic agents in myeloma cells (189, 261), which led us to study cytotoxic 
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effects of FTI-277 in a cell line engineered to overexpress Bcl-xL (31).  Our studies 
indicate Bcl-xL expression had no effect on FTI cytotoxicity (figure 32).  We extended 
our studies to include several 8226 cell lines selected for various mechanisms of drug 
resistance, including increased P-glycoprotein expression (44), reduced expression of 
topoisomerase II (68), and enhanced drug detoxification by glutathione-S-transferase 
(11).  These had no effect on cytotoxicity of FTI-277, indicating they are not cross-
resistant to FTI-277 treatment.  This is an important finding, as many myeloma patients 
initially respond to drug treatment, but then become refractory to treatment upon 
emergence of a drug-resistant population.  This work provides the rationale to study FTIs 
in clinical trials with myeloma patients who no longer respond to standard treatment 
regimens. 
 This dissertation presents work on the transcriptional regulation of the PRDI-BF1 
gene and extends these findings to studies on the modulation of the PRDM1 gene in 
PRDM1-negative lymphoma cells.  Work is also presented on the correlation between 
Ras mutation status and sensitivity to FTI-277 treatment.  These studies are extended to 
cell lines with known mechanisms of drug resistance in myeloma patients.  Cell lines 
with the drug resistant phenotype are not cross-resistant to FTI-277 treatment, 
demonstrating a potential role for use of this drug in clinical trials.  
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